User login
Keeping older patients healthy and safe as they travel
• Advise older adults to prepare a health travel kit containing all their medications and medical supplies, a list of chronic conditions, and emergency contact information, and to pack it in their carry-on luggage. C
• Instruct patients who will be airborne for ≥4 hours to stay hydrated, avoid alcohol and sedating drugs, and either do seated calf exercises or get up and move about the cabin periodically. B
• Remind patients who will spend time in developing countries to drink only bottled beverages, eat only hot food and fruit that can be peeled, and avoid ice cubes and food from street vendors. B
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
CASE Larry R, a 77-year-old retired college professor, comes in for a checkup because he is planning a trip to Kenya—on a safari he describes excitedly as “the trip of a lifetime.” He’ll be going with a group, but before he signs on he wants to be sure you think he can manage the tour’s “moderate pace.” He also thinks that he’ll “need to get some shots.”
The patient is overweight (BMI 29) and smokes a pipe daily. He has a history of hypertension, hyperlipidemia, and mild osteoarthritis in both knees and hips, all of which are well controlled.
What would you advise Professor R about the health care preparations needed for his big trip?
Chances are you have patients like Professor R—retired and relatively healthy, and endowed with a sense of adventure and the financial resources that make it possible to visit distant lands. With the nation’s 78 million baby boomers starting to reach retirement age—the oldest cohort turned 65 in 2011—you’re likely to see increasing numbers of older patients with plans for international travel in the years ahead.1
Like their younger counterparts, older people travel for a variety of reasons: Some have planned for decades to take the “trip of a lifetime” when they retire. Others plan longer excursions, sometimes referred to as an adult “gap year,” to relive a long-ago experience, volunteer in an underdeveloped country, or hike and bird watch in a rainforest. Many more are immigrants who travel to visit relatives or friends in their country of origin, usually a lower-income, environmentally depressed locale with a higher incidence of infectious diseases like malaria, typhoid, and hepatitis A. 2
And while the older traveler will have to take many of the same steps to stay healthy as his or her younger counterpart, it is the older traveler who is more likely to have chronic conditions and special needs that require additional preparation. With careful planning, however, even those with decreased faculties, ranging from impaired vision or hearing to mild cognitive impairment, can safely travel abroad.3
A pretravel visit is your opportunity to assess the patient’s fitness to make the trip being planned, ensure optimal management of chronic conditions while traveling, and identify (and recommend steps to mitigate) travel-related risks.
Morbidity and mortality abroad: A review of the risks
Although much pretravel advice centers on the prevention of tropical infectious diseases, such infections account for a very small percentage of deaths of Americans outside of the United States.1 In fact, the major health risks facing older adults traveling abroad are similar to those they face at home: Cardiovascular events are responsible for the preponderance of deaths and for half of all travel-related illnesses.1
International travel can be physically demanding for older individuals and injuries are common, accounting for a large proportion of deaths of Americans overseas4 and an estimated 25% to 38% of travel-related incidents.1,5 A third of injury-related deaths of US citizens traveling abroad involve traffic accidents, followed by homicide (17% of cases) and drowning (13%).1,5 Thus, injury prevention and management of chronic conditions are key issues to address in a pretravel consult.
Even small steps help safeguard older travelers
Older patients planning to travel abroad should schedule an appointment at least 4 to 6 weeks before their departure.2 Ask about the locale, political and environmental climate, length of stay, location and type of accommodations, accessibility to health care, and activities planned,6 which will enable you to offer both general and destination-specific health and safety tips. When advising older adults with complex comorbidities and/or particularly high-risk itineraries, referral to a travel medicine specialist should be strongly considered.
Exercise. Encourage older patients to initiate a graduated exercise program, starting several months before the trip.3 Even a modest improvement in endurance, strength, and flexibility can reduce the likelihood of injury.
Luggage. The right luggage can benefit your patients. Recommend that older patients purchase lightweight suitcases with wheels, which are easier to maneuver in and out of airports6 and less likely to cause muscle strain or musculoskeletal injury.
Insurance. If an individual becomes ill or sustains an injury overseas, the right insurance can be crucial. Advise older adults to review their health insurance policy to see whether it provides overseas coverage. If not, suggest they consider a short-term supplemental policy to cover medical care and evacuation, if needed. Recommend trip cancellation insurance, as well.
Patients should pack pills, medical supplies in a carry-on kit
Encourage all older travelers to compile a personalized travel health kit equipped with common over-the-counter (OTC) medications, prescription drugs, and any personal medical supplies they’ll need, such as a continuous positive airway pressure (CPAP) machine.1,3 Remind patients to take an ample supply of both prescription and OTC drugs, each in its original labeled container.3,6 Buying medications outside the United States is not advisable, given the variation in international regulatory standards. Stress the importance of keeping the kit in a carry-on bag.
The health kit should also include descriptions of the patient’s preexisting medical conditions, which you or a nurse or medical assistant in the practice can help to prepare; a list of prescription drugs he or she takes (using both the generic and brand names); and a copy of a recent electrocardiogram, if available, along with contact information in case of an emergency.1,3,6 A patient who uses injectable medication, such as insulin, should obtain a letter (on the practice’s letterhead) from the prescribing physician and be prepared to show the letter to airport security personnel.3,6
Staying safe in the air
The lower barometric and oxygen partial pressures found in aircraft cabins, which are pressurized at 5000 to 8000 feet, can affect both the respiratory and cardiovascular systems of older adults—particularly those with pulmonary or cardiac disorders.6,7 Individuals who do not routinely require oxygen and are able to walk the equivalent of one city block or climb one flight of stairs without shortness of breath should have little trouble compensating for the reduced oxygen in the cabin.3 Patients with stable heart failure, including New York Heart Association grades III and IV, can tolerate flights of up to one hour without additional oxygen.7
Advise older adults who will require oxygen that they are not permitted to bring their own oxygen canisters onboard an airplane.1 In-flight oxygen needs to be ordered at least 7 days before departure, and there may be a charge.7 Most airlines have medical consultants available to help patients who will need oxygen or other medical provisions.7 In addition, tour companies or travel consultants can help older patients with special needs ensure that they have access to oxygen or other medical supplies at their destination.
Thrombosis—the other in-flight risk
Sometimes referred to as “economy class syndrome” or “traveler’s thrombosis,” the venous stasis of air travel is responsible for a 3-fold increase in the risk of venous thromboembolism (VTE).8 While fatal pulmonary embolism is rare, duration of travel and risk of VTE follow a dose-response relationship, with each 2-hour increase in flight time conferring an additional 18% risk.8 Other risk factors for VTE include varicose veins, metastatic cancer, major surgery within the past 2 weeks, prior VTE, and BMI >40. Advanced age increases travelers’ risk of VTE, as well.7,8 The absolute risk, however, is low.
Among travelers older than 50 years, symptomatic VTE occurs at an estimated rate of one in 600 for flights >4 hours and one in 500 for flights >12 hours.9,10 While there is no evidence that first-class seating lowers the risk, there are preventive measures that patients can take.11
Tell patients to stay hydrated, drinking plenty of fluids but avoiding alcohol during flights of ≥4 hours’ duration. Sedating drugs should be avoided, as well. Advise anyone planning a long flight to either do seated exercises (intermittent calf contractions) or to periodically get up and walk about the cabin.9 You may also want to recommend that patients purchase below-the-knee elastic compression stockings to help decrease venous stasis.12
There is no evidence to recommend the use of aspirin to prevent VTE.12,13 But you may consider prescribing a single 40-mg dose of enoxaparin for a patient who has multiple risk factors and will be airborne for >6 hours.13
Promote safety and comfort on the ground
It is crucial to remind all travelers about the risks associated with traveling in motor vehicles in other countries. Remind patients to wear seat belts whenever they’re available; exercise caution regarding public transportation, which may be overcrowded and have an increased risk of pickpockets and robbery; and avoid riding on motorcycles and scooters. If they do opt to ride on a scooter, tell them that it’s imperative that they wear a helmet.
Minimize the effects of jet lag
Travelers of any age may experience jet lag, which occurs when the individual’s circadian clock cannot keep pace with travel across time zones.14 Notably, however, older people appear to suffer less than their younger counterparts.3 Patients traveling great distances are not likely to avoid jet lag completely, of course. Recommend the following strategies:
Start adjusting your schedule in the week before you depart, gradually shifting 2 hours toward congruence with the time zone at your destination.14
Help reset your circadian rhythm through exposure to bright light, in the morning after eastward travel and in the evening after westward travel.14
Take it easy at first. An itinerary that accounts for initial fatigue is an important nonpharmacologic management strategy.14
Avoid sedating medications, including antihistamines, tranquilizers, anti-motion sickness agents, and benzodiazepines, as these can increase falls and confusion in older adults and make jet lag worse.3
Take melatonin. A dose of 0.5 to 5 mg, taken at bedtime, may promote sleep and decrease jet lag symptoms in travelers crossing multiple time zones.14
Prepare patients to cope with heat …
Unusually hot, humid weather increases morbidity and mortality in the elderly,3,15 and older patients traveling to such climates will need to take extra precautions. Strenuous exercise in the heat should be avoided, because both thirst and the capacity to conserve salt and water decrease with age.16 Acclimatization is helped by rest, air-conditioning, loose cotton clothing, brimmed hats, and cool baths or showers.3 Diuretics may have to be adjusted for fluids lost by increased perspiration, and a discussion about a dose reduction should be included in the pretravel consult for patients who take diuretics and will be traveling to a hot, humid climate.
… and increases in altitude
For older adults, exposure to a moderate altitude (<2500 meters) is initially associated with hypoxemia and a reduced exercise capacity, until acclimatization occurs by Day 5.17,18 Although older adults generally acclimatize well, advise them to limit their activities for the first few days at a higher altitude. This is especially important for patients with coronary artery disease (CAD).
To further ease the effects of a higher altitude, advise patients to drink plenty of fluids, but little or no alcohol.19 Review the medications of an older patient who will be spending time at very high altitude. Rarely, antihypertensive medication may need to be adjusted. The body compensates for lower oxygen with a faster heart rate, and some antihypertensives may interfere with this compensatory mechanism.3
Precautions (and prophylaxis) may prevent travelers’ diarrhea
Diarrhea—among the most common travel-related conditions20—affects an estimated 30% to 70% of international travelers.2 The incidence is highest among visitors to developing countries. Most (80%-90%) of travelers’ diarrhea is due to bacterial infection,21 10% of cases are caused by parasites, and 5% to 8% by viral infection.2,22
Although increasing age lowers the risk of travelers’ diarrhea,1 older patients traveling to developing areas should be cautioned to only eat food that is served hot or fruit they can peel themselves; drink only bottled water and sealed liquids; and avoid salad, ice, and food from street vendors.1 Studies have shown, however, that tourists often get diarrhea despite these safety measures.2
Treatment and prophylaxis. Prophylactic antibiotics can prevent travelers’ diarrhea. But the increased sun sensitivity, drug-drug interactions, and gastrointestinal (GI) adverse effects associated with antibiotics limit their usefulness. Prophylaxis is indicated, however, for older adults for whom the complications of dehydration would likely be so severe that the benefits of using antibiotics to prevent diarrhea clearly outweigh the risks.23
Fluoroquinolones are a first-line treatment for travelers’ diarrhea. But increasing microbial resistance to this class of drugs, especially among Campylobacter isolates,24 may limit their usefulness in some destinations.25 Azithromycin is recommended in such cases, and has been shown to be equally effective.26,27 Single-dose therapy is well established with fluoroquinolones, but the best regimen for azithromycin (1 vs 3 days) is still under evaluation.28,29 Along with instructions on when to take an antibiotic, travelers should be given prescriptions for treatment of travelers’ diarrhea before the start of their trip. Suggest that patients purchase oral rehydration packets to take on their trip, and stress the importance of using them and staying hydrated if diarrhea develops.
Decreased upper GI acidity due to acid-blocking medications such as proton-pump inhibitors can increase the risk for many infections, including salmonella and cholera. Patients taking such medications should be made aware of the risk, and the risks vs benefits of temporarily stopping them should be discussed. Vaccination against cholera should not routinely be recommended.29,30
Vaccines and pills protect against preventable diseases
An impending trip abroad also presents an opportunity to review the patient’s immunization status, catch up on recommended vaccines, and determine whether any additional vaccinations are needed.
Herpes zoster (HZ). Patients older than 60 years should receive a single dose of the HZ vaccine, whether or not they have a history of this condition. Because this is a live virus-containing vaccine, however, it should not be given to anyone who is immunocompromised.31
MMR booster. Adults born before 1957 can be considered immune from both measles and mumps, but not rubella. There is no data on immunization to rubella, but guidelines do not recommend MMR vaccination in the elderly.1
Pneumococcal polyvalent-23 (PPV-23). One dose of the PPV-23 vaccine is indicated for all adults at age 65. This is especially important for travelers, as the prevalence of pneumococcal disease is likely higher in crowded, urban environments within less developed countries.31
Tetanus. Although tetanus is mainly a disease of the elderly, only 45% of men ages 70 years or older and 21% of women in this age group were found to have protective antibodies.1,32 In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended one dose of tetanus and diphtheria toxoid (Td) every 10 years, with a single dose of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine given in place of Td for adults older than 65.33 Despite ACIP’s recommendation, the vaccine’s use in adults 65 years and older is an off-label indication, as Tdap is only approved for use in those 11 to 64 years of age.33
Additional vaccines are recommended for travelers, with some indicated for all travelers and others that are destination-specific (TABLE).
TABLE
Which travel-related vaccines does your patient need?
Disease | Type of vaccine | Primary course | Booster/ follow-up | Route | For which destinations? |
---|---|---|---|---|---|
Vaccines for all travelers | |||||
Hepatitis A* | Killed virus | 2 doses (6-18 mo apart)† | None | IM | All |
Hepatitis B* | Recombinant viral antigen | 3 doses (0, 1, 6 mo) | None | IM | All |
Influenza | Inactivated viral | Single dose | Annually | IM | All |
Typhoid | Capsular polysaccharide Live attenuated bacteria | Single dose 4 doses (0, 2, 4, 6 mo) | 2-3 y 5 y | IM Oral | All |
Vaccines for travelers to select destinations | |||||
Japanese encephalitis | Inactivated viral | 2 doses (28 d apart) | Unknown | IM | Rural Asia‡ |
Meningococcus | Quadrivalent conjugated polysaccharide | Single dose | >10 y | IM | Sub-Saharan Africa; Saudi Arabia |
Polio | Inactivated viral | Single dose if patient had childhood series | None | SC; IM | Anyplace where polio still occurs |
Rabies | Inactivated cell culture viral | 3 doses (0, 7, 21-28 d) | None unless exposure occurs | IM | |
Yellow fever | Live attenuated virus | Single dose | 10 y | SC | Sub-Saharan Africa; tropical South America |
IM, intramuscular; SC, subcutaneous. *A combined hepatitis A/B vaccine is approved for use in older adults. †Second dose may be delayed up to 8 years without diminished efficacy. ‡Required only for prolonged stays in rural areas of Asia. Adapted from: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier; 2010. |
Meds and safety measures can minimize malaria risk
The risk of acquiring malaria differs significantly among travelers, based on destination, duration and type of travel, and season. Choice of antimalarial agents (eg, atovaquone/proguanil, chloroquine, doxycycline, mefloquine, and primaquine) should be made on an individual basis after considering these factors, as well as the resistance patterns of the countries on the patient’s itinerary, his or her medical history, and the adverse effects profile of potential agents. Because many older adults take multiple medications, the possibility of drug-drug interactions must be considered.1 You’ll find destination-specific recommendations on malaria prevention on the Centers for Disease Control and Prevention’s Travelers’ Health Web site, listed in “Travel and health: Resources for patients and physicians”. For guidance on the best drug to prescribe, you can also consult a travel medicine specialist.2
Access-able Travel Source Web site provides information for older adult travelers with special needs who need help traveling with oxygen or getting around despite decreased mobility (www.access-able.com/tips/).
American Diabetes Association publishes detailed information about traveling with diabetes (http://www.diabetes.org/living-with-diabetes/know-your-rights/discrimination/public-accommodations/air-travel-and-diabetes/).
Bureau of Consular Affairs publishes information regarding VISA and security requirements at various destinations and travel warnings (http://travel.state.gov/about/about_304.html).
Centers for Disease Control and Prevention publishes “The Yellow Book”—a reference for clinicians who advise international travelers about health risks. There is also a range of other travel-related information on its Travelers’ Health Web site (www.cdc.gov/travel/).
International Travel Medicine Society provides a global travel clinic directory (http://www.istm.org/Webforms/Searchclinics/Default.aspx?SearchType=advanced).
Transportation Security Administration Web site provides information on what can be brought on-board a plane. See “Can I bring my … through the checkpoint?” (http://apps.tsa.dhs.gov/mytsa/cib_home.aspx).
Travel Health Online offers a list of medical providers around the world (www.tripprep.com/scripts).
World Health Organization’s Travel and Health Web site provides free access to selected chapters of its book, “International Travel and Health 2012,” as well as interactive maps, information about infectious diseases and food safety, and more (www.who.int/ith/en/).
Patients should be mindful of mosquitos. Stress the importance of preventing mosquito bites (as much as possible). Advise patients traveling to mosquito-infested areas to use insect repellents containing 30% N-diethyl-meta-toluamide (DEET) and permethrin-treated clothing.34 Tell them, too, to wear long sleeves, pants, and footwear that provides full coverage.35 Ensuring that sleeping areas are properly screened or air-conditioned will further reduce the likelihood of mosquito bites.36
CASE After seeing the chief complaint listed as “Traveling to Kenya” on Professor R’s chart, you quickly review the CDC’s Travelers’ Health Web site. You encourage him to stay with his tour group and to wear a seatbelt whenever possible. You also review how to make a personalized travel health kit, and encourage him to register with the Smart Traveler Enrollment Program (STEP) (detailed at https://step.state.gov/rep) before leaving for the safari. You strongly suggest that he consider purchasing additional medical evacuation insurance, as well.
Given the prevalence of travelers’ diarrhea, along with dengue and malaria, in Kenya, you review food and water safety and avoidance of insect-transmitted diseases with the patient, and write a prescription for ciprofloxacin to be taken if he develops diarrhea. Professor R is not at high risk for VTE, but you encourage him to stay hydrated, avoid sedating medications, and be diligent about mobilization during lengthy flights. You recommend melatonin for jet lag.
To adjust to the heat, you recommend that he avoid strenuous exercise in the first few days and drink sufficient fluids throughout the trip. You administer the Tdap vaccine, an adult polio booster, and the hepatitis A vaccine, verify that he has received his pneumococcal and influenza vaccines, and prescribe an antimalarial medication.
And as you walk him toward the door, you offer him one final piece of advice: Take plenty of pictures.
CORRESPONDENCE
Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati Family Medicine Residency Program, 2123 Auburn Avenue #340, Cincinnati, OH 45219; Jeffrey.schlaudecker@uc.edu
1. Reed CM. Travel recommendations for older adults. Clin Geriatr Med. 2007;23:687-713, ix.
2. Centers for Disease Control and Prevention. Health Information for International Travel 2012. New York, NY:Oxford University Press; 2012. Available at http://wwwnc.cdc.gov/travel/page/yellowboth-2012-home.htm. Accessed December 18, 2012.
3. Cooper MC. The elderly travellers. Travel Med Infect Dis. 2006;4:218-222.
4. Guse CE, Cortes LM, Hargarten SW, et al. Fatal injuries of US citizens abroad. J Travel Med. 2007;14:279-287
5. Tonellato DJ, Guse CE, Hargarten SW. Injury deaths of US citizens abroad: new data source, old travel problem. J Travel Med. 2009;16:304-310.
6. Fenner P. Fitness to travel - assessment in the elderly and medically impaired. Aust Fam Physician. 2007;36:312-315.
7. Smith D, Toff W, Joy M, et al. Fitness to fly for passengers with cardiovascular disease. Heart. 2010;96(suppl 2):Sii1-S16.
8. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151:180-190.
9. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med. 2011;6:113-116.
10. Ansari MT, Cheung BM, Qing Huang J, et al. Traveler’s thrombosis: a systematic review. J Travel Med. 2005;12:142-154.
11. Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759-2764.
12. Cesarone MR, Belcaro G, Errichi BM, et al. The LONFLIT4—Concorde Deep Venous Thrombosis and Edema Study: prevention with travel stockings. Angiology. 2003;54:143-154.
13. Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53:1-6.
14. Sack RL. Clinical practice. Jet lag. N Engl J Med. 2010: 440-447.
15. Davies I, O’Neill PA, McLean KA, et al. Age-associated alterations in thirst and arginine vasopressin in response to a water or sodium load. Age Ageing. 1995;24:151-159.
16. Rikkert MG, Melis RJ, Claassen JA. Heat waves and dehydration in the elderly. BMJ. 2009;339:b2663.-
17. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Circulation. 1997;96:1224-1232.
18. Agostoni P, Cattadori G, Guazzi M, et al. Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med. 2000;109:450-455.
19. Higgins JP, Tuttle T, Higgins JA. Altitude and the heart: is going high safe for your cardiac patient? Am Heart J. 2010;159:25-32.
20. Gautret P, Schlagenhauf P, Gaudart J, et al. Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. Emerg Infect Dis. 2009;15:1783-1790.
21. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis. 2001;32:1706-1709.
22. Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis. 1990;12 (suppl 1):S73-S79.
23. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. Clin Infect Dis. 2002;34:628-633.
24. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect. 2004;10:868-876.
25. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341-345.
26. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165-1171.
27. Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44:338-346.
28. Shanks GD, Smoak BL, Aleman GM, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group. Clin Infect Dis. 1999;29:942-943.
29. Heatley RV, Sobala GM. Acid suppression and the gastric flora. Baillieres Clin Gastroenterol. 1993;7:167-181.
30. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006;6:361-373.
31. Vaughn JA, Miller RA. Update on immunizations in adults. Am Fam Physician. 2011;84:1015-1020.
32. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761-766.
33. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83:49-59.
34. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347:13-18.
35. Soto J, Medina F, Dember N, et al. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis. 1995;21:599-602.
36. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359:603-612.
• Advise older adults to prepare a health travel kit containing all their medications and medical supplies, a list of chronic conditions, and emergency contact information, and to pack it in their carry-on luggage. C
• Instruct patients who will be airborne for ≥4 hours to stay hydrated, avoid alcohol and sedating drugs, and either do seated calf exercises or get up and move about the cabin periodically. B
• Remind patients who will spend time in developing countries to drink only bottled beverages, eat only hot food and fruit that can be peeled, and avoid ice cubes and food from street vendors. B
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
CASE Larry R, a 77-year-old retired college professor, comes in for a checkup because he is planning a trip to Kenya—on a safari he describes excitedly as “the trip of a lifetime.” He’ll be going with a group, but before he signs on he wants to be sure you think he can manage the tour’s “moderate pace.” He also thinks that he’ll “need to get some shots.”
The patient is overweight (BMI 29) and smokes a pipe daily. He has a history of hypertension, hyperlipidemia, and mild osteoarthritis in both knees and hips, all of which are well controlled.
What would you advise Professor R about the health care preparations needed for his big trip?
Chances are you have patients like Professor R—retired and relatively healthy, and endowed with a sense of adventure and the financial resources that make it possible to visit distant lands. With the nation’s 78 million baby boomers starting to reach retirement age—the oldest cohort turned 65 in 2011—you’re likely to see increasing numbers of older patients with plans for international travel in the years ahead.1
Like their younger counterparts, older people travel for a variety of reasons: Some have planned for decades to take the “trip of a lifetime” when they retire. Others plan longer excursions, sometimes referred to as an adult “gap year,” to relive a long-ago experience, volunteer in an underdeveloped country, or hike and bird watch in a rainforest. Many more are immigrants who travel to visit relatives or friends in their country of origin, usually a lower-income, environmentally depressed locale with a higher incidence of infectious diseases like malaria, typhoid, and hepatitis A. 2
And while the older traveler will have to take many of the same steps to stay healthy as his or her younger counterpart, it is the older traveler who is more likely to have chronic conditions and special needs that require additional preparation. With careful planning, however, even those with decreased faculties, ranging from impaired vision or hearing to mild cognitive impairment, can safely travel abroad.3
A pretravel visit is your opportunity to assess the patient’s fitness to make the trip being planned, ensure optimal management of chronic conditions while traveling, and identify (and recommend steps to mitigate) travel-related risks.
Morbidity and mortality abroad: A review of the risks
Although much pretravel advice centers on the prevention of tropical infectious diseases, such infections account for a very small percentage of deaths of Americans outside of the United States.1 In fact, the major health risks facing older adults traveling abroad are similar to those they face at home: Cardiovascular events are responsible for the preponderance of deaths and for half of all travel-related illnesses.1
International travel can be physically demanding for older individuals and injuries are common, accounting for a large proportion of deaths of Americans overseas4 and an estimated 25% to 38% of travel-related incidents.1,5 A third of injury-related deaths of US citizens traveling abroad involve traffic accidents, followed by homicide (17% of cases) and drowning (13%).1,5 Thus, injury prevention and management of chronic conditions are key issues to address in a pretravel consult.
Even small steps help safeguard older travelers
Older patients planning to travel abroad should schedule an appointment at least 4 to 6 weeks before their departure.2 Ask about the locale, political and environmental climate, length of stay, location and type of accommodations, accessibility to health care, and activities planned,6 which will enable you to offer both general and destination-specific health and safety tips. When advising older adults with complex comorbidities and/or particularly high-risk itineraries, referral to a travel medicine specialist should be strongly considered.
Exercise. Encourage older patients to initiate a graduated exercise program, starting several months before the trip.3 Even a modest improvement in endurance, strength, and flexibility can reduce the likelihood of injury.
Luggage. The right luggage can benefit your patients. Recommend that older patients purchase lightweight suitcases with wheels, which are easier to maneuver in and out of airports6 and less likely to cause muscle strain or musculoskeletal injury.
Insurance. If an individual becomes ill or sustains an injury overseas, the right insurance can be crucial. Advise older adults to review their health insurance policy to see whether it provides overseas coverage. If not, suggest they consider a short-term supplemental policy to cover medical care and evacuation, if needed. Recommend trip cancellation insurance, as well.
Patients should pack pills, medical supplies in a carry-on kit
Encourage all older travelers to compile a personalized travel health kit equipped with common over-the-counter (OTC) medications, prescription drugs, and any personal medical supplies they’ll need, such as a continuous positive airway pressure (CPAP) machine.1,3 Remind patients to take an ample supply of both prescription and OTC drugs, each in its original labeled container.3,6 Buying medications outside the United States is not advisable, given the variation in international regulatory standards. Stress the importance of keeping the kit in a carry-on bag.
The health kit should also include descriptions of the patient’s preexisting medical conditions, which you or a nurse or medical assistant in the practice can help to prepare; a list of prescription drugs he or she takes (using both the generic and brand names); and a copy of a recent electrocardiogram, if available, along with contact information in case of an emergency.1,3,6 A patient who uses injectable medication, such as insulin, should obtain a letter (on the practice’s letterhead) from the prescribing physician and be prepared to show the letter to airport security personnel.3,6
Staying safe in the air
The lower barometric and oxygen partial pressures found in aircraft cabins, which are pressurized at 5000 to 8000 feet, can affect both the respiratory and cardiovascular systems of older adults—particularly those with pulmonary or cardiac disorders.6,7 Individuals who do not routinely require oxygen and are able to walk the equivalent of one city block or climb one flight of stairs without shortness of breath should have little trouble compensating for the reduced oxygen in the cabin.3 Patients with stable heart failure, including New York Heart Association grades III and IV, can tolerate flights of up to one hour without additional oxygen.7
Advise older adults who will require oxygen that they are not permitted to bring their own oxygen canisters onboard an airplane.1 In-flight oxygen needs to be ordered at least 7 days before departure, and there may be a charge.7 Most airlines have medical consultants available to help patients who will need oxygen or other medical provisions.7 In addition, tour companies or travel consultants can help older patients with special needs ensure that they have access to oxygen or other medical supplies at their destination.
Thrombosis—the other in-flight risk
Sometimes referred to as “economy class syndrome” or “traveler’s thrombosis,” the venous stasis of air travel is responsible for a 3-fold increase in the risk of venous thromboembolism (VTE).8 While fatal pulmonary embolism is rare, duration of travel and risk of VTE follow a dose-response relationship, with each 2-hour increase in flight time conferring an additional 18% risk.8 Other risk factors for VTE include varicose veins, metastatic cancer, major surgery within the past 2 weeks, prior VTE, and BMI >40. Advanced age increases travelers’ risk of VTE, as well.7,8 The absolute risk, however, is low.
Among travelers older than 50 years, symptomatic VTE occurs at an estimated rate of one in 600 for flights >4 hours and one in 500 for flights >12 hours.9,10 While there is no evidence that first-class seating lowers the risk, there are preventive measures that patients can take.11
Tell patients to stay hydrated, drinking plenty of fluids but avoiding alcohol during flights of ≥4 hours’ duration. Sedating drugs should be avoided, as well. Advise anyone planning a long flight to either do seated exercises (intermittent calf contractions) or to periodically get up and walk about the cabin.9 You may also want to recommend that patients purchase below-the-knee elastic compression stockings to help decrease venous stasis.12
There is no evidence to recommend the use of aspirin to prevent VTE.12,13 But you may consider prescribing a single 40-mg dose of enoxaparin for a patient who has multiple risk factors and will be airborne for >6 hours.13
Promote safety and comfort on the ground
It is crucial to remind all travelers about the risks associated with traveling in motor vehicles in other countries. Remind patients to wear seat belts whenever they’re available; exercise caution regarding public transportation, which may be overcrowded and have an increased risk of pickpockets and robbery; and avoid riding on motorcycles and scooters. If they do opt to ride on a scooter, tell them that it’s imperative that they wear a helmet.
Minimize the effects of jet lag
Travelers of any age may experience jet lag, which occurs when the individual’s circadian clock cannot keep pace with travel across time zones.14 Notably, however, older people appear to suffer less than their younger counterparts.3 Patients traveling great distances are not likely to avoid jet lag completely, of course. Recommend the following strategies:
Start adjusting your schedule in the week before you depart, gradually shifting 2 hours toward congruence with the time zone at your destination.14
Help reset your circadian rhythm through exposure to bright light, in the morning after eastward travel and in the evening after westward travel.14
Take it easy at first. An itinerary that accounts for initial fatigue is an important nonpharmacologic management strategy.14
Avoid sedating medications, including antihistamines, tranquilizers, anti-motion sickness agents, and benzodiazepines, as these can increase falls and confusion in older adults and make jet lag worse.3
Take melatonin. A dose of 0.5 to 5 mg, taken at bedtime, may promote sleep and decrease jet lag symptoms in travelers crossing multiple time zones.14
Prepare patients to cope with heat …
Unusually hot, humid weather increases morbidity and mortality in the elderly,3,15 and older patients traveling to such climates will need to take extra precautions. Strenuous exercise in the heat should be avoided, because both thirst and the capacity to conserve salt and water decrease with age.16 Acclimatization is helped by rest, air-conditioning, loose cotton clothing, brimmed hats, and cool baths or showers.3 Diuretics may have to be adjusted for fluids lost by increased perspiration, and a discussion about a dose reduction should be included in the pretravel consult for patients who take diuretics and will be traveling to a hot, humid climate.
… and increases in altitude
For older adults, exposure to a moderate altitude (<2500 meters) is initially associated with hypoxemia and a reduced exercise capacity, until acclimatization occurs by Day 5.17,18 Although older adults generally acclimatize well, advise them to limit their activities for the first few days at a higher altitude. This is especially important for patients with coronary artery disease (CAD).
To further ease the effects of a higher altitude, advise patients to drink plenty of fluids, but little or no alcohol.19 Review the medications of an older patient who will be spending time at very high altitude. Rarely, antihypertensive medication may need to be adjusted. The body compensates for lower oxygen with a faster heart rate, and some antihypertensives may interfere with this compensatory mechanism.3
Precautions (and prophylaxis) may prevent travelers’ diarrhea
Diarrhea—among the most common travel-related conditions20—affects an estimated 30% to 70% of international travelers.2 The incidence is highest among visitors to developing countries. Most (80%-90%) of travelers’ diarrhea is due to bacterial infection,21 10% of cases are caused by parasites, and 5% to 8% by viral infection.2,22
Although increasing age lowers the risk of travelers’ diarrhea,1 older patients traveling to developing areas should be cautioned to only eat food that is served hot or fruit they can peel themselves; drink only bottled water and sealed liquids; and avoid salad, ice, and food from street vendors.1 Studies have shown, however, that tourists often get diarrhea despite these safety measures.2
Treatment and prophylaxis. Prophylactic antibiotics can prevent travelers’ diarrhea. But the increased sun sensitivity, drug-drug interactions, and gastrointestinal (GI) adverse effects associated with antibiotics limit their usefulness. Prophylaxis is indicated, however, for older adults for whom the complications of dehydration would likely be so severe that the benefits of using antibiotics to prevent diarrhea clearly outweigh the risks.23
Fluoroquinolones are a first-line treatment for travelers’ diarrhea. But increasing microbial resistance to this class of drugs, especially among Campylobacter isolates,24 may limit their usefulness in some destinations.25 Azithromycin is recommended in such cases, and has been shown to be equally effective.26,27 Single-dose therapy is well established with fluoroquinolones, but the best regimen for azithromycin (1 vs 3 days) is still under evaluation.28,29 Along with instructions on when to take an antibiotic, travelers should be given prescriptions for treatment of travelers’ diarrhea before the start of their trip. Suggest that patients purchase oral rehydration packets to take on their trip, and stress the importance of using them and staying hydrated if diarrhea develops.
Decreased upper GI acidity due to acid-blocking medications such as proton-pump inhibitors can increase the risk for many infections, including salmonella and cholera. Patients taking such medications should be made aware of the risk, and the risks vs benefits of temporarily stopping them should be discussed. Vaccination against cholera should not routinely be recommended.29,30
Vaccines and pills protect against preventable diseases
An impending trip abroad also presents an opportunity to review the patient’s immunization status, catch up on recommended vaccines, and determine whether any additional vaccinations are needed.
Herpes zoster (HZ). Patients older than 60 years should receive a single dose of the HZ vaccine, whether or not they have a history of this condition. Because this is a live virus-containing vaccine, however, it should not be given to anyone who is immunocompromised.31
MMR booster. Adults born before 1957 can be considered immune from both measles and mumps, but not rubella. There is no data on immunization to rubella, but guidelines do not recommend MMR vaccination in the elderly.1
Pneumococcal polyvalent-23 (PPV-23). One dose of the PPV-23 vaccine is indicated for all adults at age 65. This is especially important for travelers, as the prevalence of pneumococcal disease is likely higher in crowded, urban environments within less developed countries.31
Tetanus. Although tetanus is mainly a disease of the elderly, only 45% of men ages 70 years or older and 21% of women in this age group were found to have protective antibodies.1,32 In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended one dose of tetanus and diphtheria toxoid (Td) every 10 years, with a single dose of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine given in place of Td for adults older than 65.33 Despite ACIP’s recommendation, the vaccine’s use in adults 65 years and older is an off-label indication, as Tdap is only approved for use in those 11 to 64 years of age.33
Additional vaccines are recommended for travelers, with some indicated for all travelers and others that are destination-specific (TABLE).
TABLE
Which travel-related vaccines does your patient need?
Disease | Type of vaccine | Primary course | Booster/ follow-up | Route | For which destinations? |
---|---|---|---|---|---|
Vaccines for all travelers | |||||
Hepatitis A* | Killed virus | 2 doses (6-18 mo apart)† | None | IM | All |
Hepatitis B* | Recombinant viral antigen | 3 doses (0, 1, 6 mo) | None | IM | All |
Influenza | Inactivated viral | Single dose | Annually | IM | All |
Typhoid | Capsular polysaccharide Live attenuated bacteria | Single dose 4 doses (0, 2, 4, 6 mo) | 2-3 y 5 y | IM Oral | All |
Vaccines for travelers to select destinations | |||||
Japanese encephalitis | Inactivated viral | 2 doses (28 d apart) | Unknown | IM | Rural Asia‡ |
Meningococcus | Quadrivalent conjugated polysaccharide | Single dose | >10 y | IM | Sub-Saharan Africa; Saudi Arabia |
Polio | Inactivated viral | Single dose if patient had childhood series | None | SC; IM | Anyplace where polio still occurs |
Rabies | Inactivated cell culture viral | 3 doses (0, 7, 21-28 d) | None unless exposure occurs | IM | |
Yellow fever | Live attenuated virus | Single dose | 10 y | SC | Sub-Saharan Africa; tropical South America |
IM, intramuscular; SC, subcutaneous. *A combined hepatitis A/B vaccine is approved for use in older adults. †Second dose may be delayed up to 8 years without diminished efficacy. ‡Required only for prolonged stays in rural areas of Asia. Adapted from: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier; 2010. |
Meds and safety measures can minimize malaria risk
The risk of acquiring malaria differs significantly among travelers, based on destination, duration and type of travel, and season. Choice of antimalarial agents (eg, atovaquone/proguanil, chloroquine, doxycycline, mefloquine, and primaquine) should be made on an individual basis after considering these factors, as well as the resistance patterns of the countries on the patient’s itinerary, his or her medical history, and the adverse effects profile of potential agents. Because many older adults take multiple medications, the possibility of drug-drug interactions must be considered.1 You’ll find destination-specific recommendations on malaria prevention on the Centers for Disease Control and Prevention’s Travelers’ Health Web site, listed in “Travel and health: Resources for patients and physicians”. For guidance on the best drug to prescribe, you can also consult a travel medicine specialist.2
Access-able Travel Source Web site provides information for older adult travelers with special needs who need help traveling with oxygen or getting around despite decreased mobility (www.access-able.com/tips/).
American Diabetes Association publishes detailed information about traveling with diabetes (http://www.diabetes.org/living-with-diabetes/know-your-rights/discrimination/public-accommodations/air-travel-and-diabetes/).
Bureau of Consular Affairs publishes information regarding VISA and security requirements at various destinations and travel warnings (http://travel.state.gov/about/about_304.html).
Centers for Disease Control and Prevention publishes “The Yellow Book”—a reference for clinicians who advise international travelers about health risks. There is also a range of other travel-related information on its Travelers’ Health Web site (www.cdc.gov/travel/).
International Travel Medicine Society provides a global travel clinic directory (http://www.istm.org/Webforms/Searchclinics/Default.aspx?SearchType=advanced).
Transportation Security Administration Web site provides information on what can be brought on-board a plane. See “Can I bring my … through the checkpoint?” (http://apps.tsa.dhs.gov/mytsa/cib_home.aspx).
Travel Health Online offers a list of medical providers around the world (www.tripprep.com/scripts).
World Health Organization’s Travel and Health Web site provides free access to selected chapters of its book, “International Travel and Health 2012,” as well as interactive maps, information about infectious diseases and food safety, and more (www.who.int/ith/en/).
Patients should be mindful of mosquitos. Stress the importance of preventing mosquito bites (as much as possible). Advise patients traveling to mosquito-infested areas to use insect repellents containing 30% N-diethyl-meta-toluamide (DEET) and permethrin-treated clothing.34 Tell them, too, to wear long sleeves, pants, and footwear that provides full coverage.35 Ensuring that sleeping areas are properly screened or air-conditioned will further reduce the likelihood of mosquito bites.36
CASE After seeing the chief complaint listed as “Traveling to Kenya” on Professor R’s chart, you quickly review the CDC’s Travelers’ Health Web site. You encourage him to stay with his tour group and to wear a seatbelt whenever possible. You also review how to make a personalized travel health kit, and encourage him to register with the Smart Traveler Enrollment Program (STEP) (detailed at https://step.state.gov/rep) before leaving for the safari. You strongly suggest that he consider purchasing additional medical evacuation insurance, as well.
Given the prevalence of travelers’ diarrhea, along with dengue and malaria, in Kenya, you review food and water safety and avoidance of insect-transmitted diseases with the patient, and write a prescription for ciprofloxacin to be taken if he develops diarrhea. Professor R is not at high risk for VTE, but you encourage him to stay hydrated, avoid sedating medications, and be diligent about mobilization during lengthy flights. You recommend melatonin for jet lag.
To adjust to the heat, you recommend that he avoid strenuous exercise in the first few days and drink sufficient fluids throughout the trip. You administer the Tdap vaccine, an adult polio booster, and the hepatitis A vaccine, verify that he has received his pneumococcal and influenza vaccines, and prescribe an antimalarial medication.
And as you walk him toward the door, you offer him one final piece of advice: Take plenty of pictures.
CORRESPONDENCE
Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati Family Medicine Residency Program, 2123 Auburn Avenue #340, Cincinnati, OH 45219; Jeffrey.schlaudecker@uc.edu
• Advise older adults to prepare a health travel kit containing all their medications and medical supplies, a list of chronic conditions, and emergency contact information, and to pack it in their carry-on luggage. C
• Instruct patients who will be airborne for ≥4 hours to stay hydrated, avoid alcohol and sedating drugs, and either do seated calf exercises or get up and move about the cabin periodically. B
• Remind patients who will spend time in developing countries to drink only bottled beverages, eat only hot food and fruit that can be peeled, and avoid ice cubes and food from street vendors. B
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
CASE Larry R, a 77-year-old retired college professor, comes in for a checkup because he is planning a trip to Kenya—on a safari he describes excitedly as “the trip of a lifetime.” He’ll be going with a group, but before he signs on he wants to be sure you think he can manage the tour’s “moderate pace.” He also thinks that he’ll “need to get some shots.”
The patient is overweight (BMI 29) and smokes a pipe daily. He has a history of hypertension, hyperlipidemia, and mild osteoarthritis in both knees and hips, all of which are well controlled.
What would you advise Professor R about the health care preparations needed for his big trip?
Chances are you have patients like Professor R—retired and relatively healthy, and endowed with a sense of adventure and the financial resources that make it possible to visit distant lands. With the nation’s 78 million baby boomers starting to reach retirement age—the oldest cohort turned 65 in 2011—you’re likely to see increasing numbers of older patients with plans for international travel in the years ahead.1
Like their younger counterparts, older people travel for a variety of reasons: Some have planned for decades to take the “trip of a lifetime” when they retire. Others plan longer excursions, sometimes referred to as an adult “gap year,” to relive a long-ago experience, volunteer in an underdeveloped country, or hike and bird watch in a rainforest. Many more are immigrants who travel to visit relatives or friends in their country of origin, usually a lower-income, environmentally depressed locale with a higher incidence of infectious diseases like malaria, typhoid, and hepatitis A. 2
And while the older traveler will have to take many of the same steps to stay healthy as his or her younger counterpart, it is the older traveler who is more likely to have chronic conditions and special needs that require additional preparation. With careful planning, however, even those with decreased faculties, ranging from impaired vision or hearing to mild cognitive impairment, can safely travel abroad.3
A pretravel visit is your opportunity to assess the patient’s fitness to make the trip being planned, ensure optimal management of chronic conditions while traveling, and identify (and recommend steps to mitigate) travel-related risks.
Morbidity and mortality abroad: A review of the risks
Although much pretravel advice centers on the prevention of tropical infectious diseases, such infections account for a very small percentage of deaths of Americans outside of the United States.1 In fact, the major health risks facing older adults traveling abroad are similar to those they face at home: Cardiovascular events are responsible for the preponderance of deaths and for half of all travel-related illnesses.1
International travel can be physically demanding for older individuals and injuries are common, accounting for a large proportion of deaths of Americans overseas4 and an estimated 25% to 38% of travel-related incidents.1,5 A third of injury-related deaths of US citizens traveling abroad involve traffic accidents, followed by homicide (17% of cases) and drowning (13%).1,5 Thus, injury prevention and management of chronic conditions are key issues to address in a pretravel consult.
Even small steps help safeguard older travelers
Older patients planning to travel abroad should schedule an appointment at least 4 to 6 weeks before their departure.2 Ask about the locale, political and environmental climate, length of stay, location and type of accommodations, accessibility to health care, and activities planned,6 which will enable you to offer both general and destination-specific health and safety tips. When advising older adults with complex comorbidities and/or particularly high-risk itineraries, referral to a travel medicine specialist should be strongly considered.
Exercise. Encourage older patients to initiate a graduated exercise program, starting several months before the trip.3 Even a modest improvement in endurance, strength, and flexibility can reduce the likelihood of injury.
Luggage. The right luggage can benefit your patients. Recommend that older patients purchase lightweight suitcases with wheels, which are easier to maneuver in and out of airports6 and less likely to cause muscle strain or musculoskeletal injury.
Insurance. If an individual becomes ill or sustains an injury overseas, the right insurance can be crucial. Advise older adults to review their health insurance policy to see whether it provides overseas coverage. If not, suggest they consider a short-term supplemental policy to cover medical care and evacuation, if needed. Recommend trip cancellation insurance, as well.
Patients should pack pills, medical supplies in a carry-on kit
Encourage all older travelers to compile a personalized travel health kit equipped with common over-the-counter (OTC) medications, prescription drugs, and any personal medical supplies they’ll need, such as a continuous positive airway pressure (CPAP) machine.1,3 Remind patients to take an ample supply of both prescription and OTC drugs, each in its original labeled container.3,6 Buying medications outside the United States is not advisable, given the variation in international regulatory standards. Stress the importance of keeping the kit in a carry-on bag.
The health kit should also include descriptions of the patient’s preexisting medical conditions, which you or a nurse or medical assistant in the practice can help to prepare; a list of prescription drugs he or she takes (using both the generic and brand names); and a copy of a recent electrocardiogram, if available, along with contact information in case of an emergency.1,3,6 A patient who uses injectable medication, such as insulin, should obtain a letter (on the practice’s letterhead) from the prescribing physician and be prepared to show the letter to airport security personnel.3,6
Staying safe in the air
The lower barometric and oxygen partial pressures found in aircraft cabins, which are pressurized at 5000 to 8000 feet, can affect both the respiratory and cardiovascular systems of older adults—particularly those with pulmonary or cardiac disorders.6,7 Individuals who do not routinely require oxygen and are able to walk the equivalent of one city block or climb one flight of stairs without shortness of breath should have little trouble compensating for the reduced oxygen in the cabin.3 Patients with stable heart failure, including New York Heart Association grades III and IV, can tolerate flights of up to one hour without additional oxygen.7
Advise older adults who will require oxygen that they are not permitted to bring their own oxygen canisters onboard an airplane.1 In-flight oxygen needs to be ordered at least 7 days before departure, and there may be a charge.7 Most airlines have medical consultants available to help patients who will need oxygen or other medical provisions.7 In addition, tour companies or travel consultants can help older patients with special needs ensure that they have access to oxygen or other medical supplies at their destination.
Thrombosis—the other in-flight risk
Sometimes referred to as “economy class syndrome” or “traveler’s thrombosis,” the venous stasis of air travel is responsible for a 3-fold increase in the risk of venous thromboembolism (VTE).8 While fatal pulmonary embolism is rare, duration of travel and risk of VTE follow a dose-response relationship, with each 2-hour increase in flight time conferring an additional 18% risk.8 Other risk factors for VTE include varicose veins, metastatic cancer, major surgery within the past 2 weeks, prior VTE, and BMI >40. Advanced age increases travelers’ risk of VTE, as well.7,8 The absolute risk, however, is low.
Among travelers older than 50 years, symptomatic VTE occurs at an estimated rate of one in 600 for flights >4 hours and one in 500 for flights >12 hours.9,10 While there is no evidence that first-class seating lowers the risk, there are preventive measures that patients can take.11
Tell patients to stay hydrated, drinking plenty of fluids but avoiding alcohol during flights of ≥4 hours’ duration. Sedating drugs should be avoided, as well. Advise anyone planning a long flight to either do seated exercises (intermittent calf contractions) or to periodically get up and walk about the cabin.9 You may also want to recommend that patients purchase below-the-knee elastic compression stockings to help decrease venous stasis.12
There is no evidence to recommend the use of aspirin to prevent VTE.12,13 But you may consider prescribing a single 40-mg dose of enoxaparin for a patient who has multiple risk factors and will be airborne for >6 hours.13
Promote safety and comfort on the ground
It is crucial to remind all travelers about the risks associated with traveling in motor vehicles in other countries. Remind patients to wear seat belts whenever they’re available; exercise caution regarding public transportation, which may be overcrowded and have an increased risk of pickpockets and robbery; and avoid riding on motorcycles and scooters. If they do opt to ride on a scooter, tell them that it’s imperative that they wear a helmet.
Minimize the effects of jet lag
Travelers of any age may experience jet lag, which occurs when the individual’s circadian clock cannot keep pace with travel across time zones.14 Notably, however, older people appear to suffer less than their younger counterparts.3 Patients traveling great distances are not likely to avoid jet lag completely, of course. Recommend the following strategies:
Start adjusting your schedule in the week before you depart, gradually shifting 2 hours toward congruence with the time zone at your destination.14
Help reset your circadian rhythm through exposure to bright light, in the morning after eastward travel and in the evening after westward travel.14
Take it easy at first. An itinerary that accounts for initial fatigue is an important nonpharmacologic management strategy.14
Avoid sedating medications, including antihistamines, tranquilizers, anti-motion sickness agents, and benzodiazepines, as these can increase falls and confusion in older adults and make jet lag worse.3
Take melatonin. A dose of 0.5 to 5 mg, taken at bedtime, may promote sleep and decrease jet lag symptoms in travelers crossing multiple time zones.14
Prepare patients to cope with heat …
Unusually hot, humid weather increases morbidity and mortality in the elderly,3,15 and older patients traveling to such climates will need to take extra precautions. Strenuous exercise in the heat should be avoided, because both thirst and the capacity to conserve salt and water decrease with age.16 Acclimatization is helped by rest, air-conditioning, loose cotton clothing, brimmed hats, and cool baths or showers.3 Diuretics may have to be adjusted for fluids lost by increased perspiration, and a discussion about a dose reduction should be included in the pretravel consult for patients who take diuretics and will be traveling to a hot, humid climate.
… and increases in altitude
For older adults, exposure to a moderate altitude (<2500 meters) is initially associated with hypoxemia and a reduced exercise capacity, until acclimatization occurs by Day 5.17,18 Although older adults generally acclimatize well, advise them to limit their activities for the first few days at a higher altitude. This is especially important for patients with coronary artery disease (CAD).
To further ease the effects of a higher altitude, advise patients to drink plenty of fluids, but little or no alcohol.19 Review the medications of an older patient who will be spending time at very high altitude. Rarely, antihypertensive medication may need to be adjusted. The body compensates for lower oxygen with a faster heart rate, and some antihypertensives may interfere with this compensatory mechanism.3
Precautions (and prophylaxis) may prevent travelers’ diarrhea
Diarrhea—among the most common travel-related conditions20—affects an estimated 30% to 70% of international travelers.2 The incidence is highest among visitors to developing countries. Most (80%-90%) of travelers’ diarrhea is due to bacterial infection,21 10% of cases are caused by parasites, and 5% to 8% by viral infection.2,22
Although increasing age lowers the risk of travelers’ diarrhea,1 older patients traveling to developing areas should be cautioned to only eat food that is served hot or fruit they can peel themselves; drink only bottled water and sealed liquids; and avoid salad, ice, and food from street vendors.1 Studies have shown, however, that tourists often get diarrhea despite these safety measures.2
Treatment and prophylaxis. Prophylactic antibiotics can prevent travelers’ diarrhea. But the increased sun sensitivity, drug-drug interactions, and gastrointestinal (GI) adverse effects associated with antibiotics limit their usefulness. Prophylaxis is indicated, however, for older adults for whom the complications of dehydration would likely be so severe that the benefits of using antibiotics to prevent diarrhea clearly outweigh the risks.23
Fluoroquinolones are a first-line treatment for travelers’ diarrhea. But increasing microbial resistance to this class of drugs, especially among Campylobacter isolates,24 may limit their usefulness in some destinations.25 Azithromycin is recommended in such cases, and has been shown to be equally effective.26,27 Single-dose therapy is well established with fluoroquinolones, but the best regimen for azithromycin (1 vs 3 days) is still under evaluation.28,29 Along with instructions on when to take an antibiotic, travelers should be given prescriptions for treatment of travelers’ diarrhea before the start of their trip. Suggest that patients purchase oral rehydration packets to take on their trip, and stress the importance of using them and staying hydrated if diarrhea develops.
Decreased upper GI acidity due to acid-blocking medications such as proton-pump inhibitors can increase the risk for many infections, including salmonella and cholera. Patients taking such medications should be made aware of the risk, and the risks vs benefits of temporarily stopping them should be discussed. Vaccination against cholera should not routinely be recommended.29,30
Vaccines and pills protect against preventable diseases
An impending trip abroad also presents an opportunity to review the patient’s immunization status, catch up on recommended vaccines, and determine whether any additional vaccinations are needed.
Herpes zoster (HZ). Patients older than 60 years should receive a single dose of the HZ vaccine, whether or not they have a history of this condition. Because this is a live virus-containing vaccine, however, it should not be given to anyone who is immunocompromised.31
MMR booster. Adults born before 1957 can be considered immune from both measles and mumps, but not rubella. There is no data on immunization to rubella, but guidelines do not recommend MMR vaccination in the elderly.1
Pneumococcal polyvalent-23 (PPV-23). One dose of the PPV-23 vaccine is indicated for all adults at age 65. This is especially important for travelers, as the prevalence of pneumococcal disease is likely higher in crowded, urban environments within less developed countries.31
Tetanus. Although tetanus is mainly a disease of the elderly, only 45% of men ages 70 years or older and 21% of women in this age group were found to have protective antibodies.1,32 In 2011, the Advisory Committee on Immunization Practices (ACIP) recommended one dose of tetanus and diphtheria toxoid (Td) every 10 years, with a single dose of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine given in place of Td for adults older than 65.33 Despite ACIP’s recommendation, the vaccine’s use in adults 65 years and older is an off-label indication, as Tdap is only approved for use in those 11 to 64 years of age.33
Additional vaccines are recommended for travelers, with some indicated for all travelers and others that are destination-specific (TABLE).
TABLE
Which travel-related vaccines does your patient need?
Disease | Type of vaccine | Primary course | Booster/ follow-up | Route | For which destinations? |
---|---|---|---|---|---|
Vaccines for all travelers | |||||
Hepatitis A* | Killed virus | 2 doses (6-18 mo apart)† | None | IM | All |
Hepatitis B* | Recombinant viral antigen | 3 doses (0, 1, 6 mo) | None | IM | All |
Influenza | Inactivated viral | Single dose | Annually | IM | All |
Typhoid | Capsular polysaccharide Live attenuated bacteria | Single dose 4 doses (0, 2, 4, 6 mo) | 2-3 y 5 y | IM Oral | All |
Vaccines for travelers to select destinations | |||||
Japanese encephalitis | Inactivated viral | 2 doses (28 d apart) | Unknown | IM | Rural Asia‡ |
Meningococcus | Quadrivalent conjugated polysaccharide | Single dose | >10 y | IM | Sub-Saharan Africa; Saudi Arabia |
Polio | Inactivated viral | Single dose if patient had childhood series | None | SC; IM | Anyplace where polio still occurs |
Rabies | Inactivated cell culture viral | 3 doses (0, 7, 21-28 d) | None unless exposure occurs | IM | |
Yellow fever | Live attenuated virus | Single dose | 10 y | SC | Sub-Saharan Africa; tropical South America |
IM, intramuscular; SC, subcutaneous. *A combined hepatitis A/B vaccine is approved for use in older adults. †Second dose may be delayed up to 8 years without diminished efficacy. ‡Required only for prolonged stays in rural areas of Asia. Adapted from: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier; 2010. |
Meds and safety measures can minimize malaria risk
The risk of acquiring malaria differs significantly among travelers, based on destination, duration and type of travel, and season. Choice of antimalarial agents (eg, atovaquone/proguanil, chloroquine, doxycycline, mefloquine, and primaquine) should be made on an individual basis after considering these factors, as well as the resistance patterns of the countries on the patient’s itinerary, his or her medical history, and the adverse effects profile of potential agents. Because many older adults take multiple medications, the possibility of drug-drug interactions must be considered.1 You’ll find destination-specific recommendations on malaria prevention on the Centers for Disease Control and Prevention’s Travelers’ Health Web site, listed in “Travel and health: Resources for patients and physicians”. For guidance on the best drug to prescribe, you can also consult a travel medicine specialist.2
Access-able Travel Source Web site provides information for older adult travelers with special needs who need help traveling with oxygen or getting around despite decreased mobility (www.access-able.com/tips/).
American Diabetes Association publishes detailed information about traveling with diabetes (http://www.diabetes.org/living-with-diabetes/know-your-rights/discrimination/public-accommodations/air-travel-and-diabetes/).
Bureau of Consular Affairs publishes information regarding VISA and security requirements at various destinations and travel warnings (http://travel.state.gov/about/about_304.html).
Centers for Disease Control and Prevention publishes “The Yellow Book”—a reference for clinicians who advise international travelers about health risks. There is also a range of other travel-related information on its Travelers’ Health Web site (www.cdc.gov/travel/).
International Travel Medicine Society provides a global travel clinic directory (http://www.istm.org/Webforms/Searchclinics/Default.aspx?SearchType=advanced).
Transportation Security Administration Web site provides information on what can be brought on-board a plane. See “Can I bring my … through the checkpoint?” (http://apps.tsa.dhs.gov/mytsa/cib_home.aspx).
Travel Health Online offers a list of medical providers around the world (www.tripprep.com/scripts).
World Health Organization’s Travel and Health Web site provides free access to selected chapters of its book, “International Travel and Health 2012,” as well as interactive maps, information about infectious diseases and food safety, and more (www.who.int/ith/en/).
Patients should be mindful of mosquitos. Stress the importance of preventing mosquito bites (as much as possible). Advise patients traveling to mosquito-infested areas to use insect repellents containing 30% N-diethyl-meta-toluamide (DEET) and permethrin-treated clothing.34 Tell them, too, to wear long sleeves, pants, and footwear that provides full coverage.35 Ensuring that sleeping areas are properly screened or air-conditioned will further reduce the likelihood of mosquito bites.36
CASE After seeing the chief complaint listed as “Traveling to Kenya” on Professor R’s chart, you quickly review the CDC’s Travelers’ Health Web site. You encourage him to stay with his tour group and to wear a seatbelt whenever possible. You also review how to make a personalized travel health kit, and encourage him to register with the Smart Traveler Enrollment Program (STEP) (detailed at https://step.state.gov/rep) before leaving for the safari. You strongly suggest that he consider purchasing additional medical evacuation insurance, as well.
Given the prevalence of travelers’ diarrhea, along with dengue and malaria, in Kenya, you review food and water safety and avoidance of insect-transmitted diseases with the patient, and write a prescription for ciprofloxacin to be taken if he develops diarrhea. Professor R is not at high risk for VTE, but you encourage him to stay hydrated, avoid sedating medications, and be diligent about mobilization during lengthy flights. You recommend melatonin for jet lag.
To adjust to the heat, you recommend that he avoid strenuous exercise in the first few days and drink sufficient fluids throughout the trip. You administer the Tdap vaccine, an adult polio booster, and the hepatitis A vaccine, verify that he has received his pneumococcal and influenza vaccines, and prescribe an antimalarial medication.
And as you walk him toward the door, you offer him one final piece of advice: Take plenty of pictures.
CORRESPONDENCE
Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati Family Medicine Residency Program, 2123 Auburn Avenue #340, Cincinnati, OH 45219; Jeffrey.schlaudecker@uc.edu
1. Reed CM. Travel recommendations for older adults. Clin Geriatr Med. 2007;23:687-713, ix.
2. Centers for Disease Control and Prevention. Health Information for International Travel 2012. New York, NY:Oxford University Press; 2012. Available at http://wwwnc.cdc.gov/travel/page/yellowboth-2012-home.htm. Accessed December 18, 2012.
3. Cooper MC. The elderly travellers. Travel Med Infect Dis. 2006;4:218-222.
4. Guse CE, Cortes LM, Hargarten SW, et al. Fatal injuries of US citizens abroad. J Travel Med. 2007;14:279-287
5. Tonellato DJ, Guse CE, Hargarten SW. Injury deaths of US citizens abroad: new data source, old travel problem. J Travel Med. 2009;16:304-310.
6. Fenner P. Fitness to travel - assessment in the elderly and medically impaired. Aust Fam Physician. 2007;36:312-315.
7. Smith D, Toff W, Joy M, et al. Fitness to fly for passengers with cardiovascular disease. Heart. 2010;96(suppl 2):Sii1-S16.
8. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151:180-190.
9. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med. 2011;6:113-116.
10. Ansari MT, Cheung BM, Qing Huang J, et al. Traveler’s thrombosis: a systematic review. J Travel Med. 2005;12:142-154.
11. Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759-2764.
12. Cesarone MR, Belcaro G, Errichi BM, et al. The LONFLIT4—Concorde Deep Venous Thrombosis and Edema Study: prevention with travel stockings. Angiology. 2003;54:143-154.
13. Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53:1-6.
14. Sack RL. Clinical practice. Jet lag. N Engl J Med. 2010: 440-447.
15. Davies I, O’Neill PA, McLean KA, et al. Age-associated alterations in thirst and arginine vasopressin in response to a water or sodium load. Age Ageing. 1995;24:151-159.
16. Rikkert MG, Melis RJ, Claassen JA. Heat waves and dehydration in the elderly. BMJ. 2009;339:b2663.-
17. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Circulation. 1997;96:1224-1232.
18. Agostoni P, Cattadori G, Guazzi M, et al. Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med. 2000;109:450-455.
19. Higgins JP, Tuttle T, Higgins JA. Altitude and the heart: is going high safe for your cardiac patient? Am Heart J. 2010;159:25-32.
20. Gautret P, Schlagenhauf P, Gaudart J, et al. Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. Emerg Infect Dis. 2009;15:1783-1790.
21. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis. 2001;32:1706-1709.
22. Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis. 1990;12 (suppl 1):S73-S79.
23. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. Clin Infect Dis. 2002;34:628-633.
24. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect. 2004;10:868-876.
25. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341-345.
26. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165-1171.
27. Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44:338-346.
28. Shanks GD, Smoak BL, Aleman GM, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group. Clin Infect Dis. 1999;29:942-943.
29. Heatley RV, Sobala GM. Acid suppression and the gastric flora. Baillieres Clin Gastroenterol. 1993;7:167-181.
30. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006;6:361-373.
31. Vaughn JA, Miller RA. Update on immunizations in adults. Am Fam Physician. 2011;84:1015-1020.
32. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761-766.
33. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83:49-59.
34. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347:13-18.
35. Soto J, Medina F, Dember N, et al. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis. 1995;21:599-602.
36. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359:603-612.
1. Reed CM. Travel recommendations for older adults. Clin Geriatr Med. 2007;23:687-713, ix.
2. Centers for Disease Control and Prevention. Health Information for International Travel 2012. New York, NY:Oxford University Press; 2012. Available at http://wwwnc.cdc.gov/travel/page/yellowboth-2012-home.htm. Accessed December 18, 2012.
3. Cooper MC. The elderly travellers. Travel Med Infect Dis. 2006;4:218-222.
4. Guse CE, Cortes LM, Hargarten SW, et al. Fatal injuries of US citizens abroad. J Travel Med. 2007;14:279-287
5. Tonellato DJ, Guse CE, Hargarten SW. Injury deaths of US citizens abroad: new data source, old travel problem. J Travel Med. 2009;16:304-310.
6. Fenner P. Fitness to travel - assessment in the elderly and medically impaired. Aust Fam Physician. 2007;36:312-315.
7. Smith D, Toff W, Joy M, et al. Fitness to fly for passengers with cardiovascular disease. Heart. 2010;96(suppl 2):Sii1-S16.
8. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151:180-190.
9. Gavish I, Brenner B. Air travel and the risk of thromboembolism. Intern Emerg Med. 2011;6:113-116.
10. Ansari MT, Cheung BM, Qing Huang J, et al. Traveler’s thrombosis: a systematic review. J Travel Med. 2005;12:142-154.
11. Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759-2764.
12. Cesarone MR, Belcaro G, Errichi BM, et al. The LONFLIT4—Concorde Deep Venous Thrombosis and Edema Study: prevention with travel stockings. Angiology. 2003;54:143-154.
13. Cesarone MR, Belcaro G, Nicolaides AN, et al. Venous thrombosis from air travel: the LONFLIT3 study—prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology. 2002;53:1-6.
14. Sack RL. Clinical practice. Jet lag. N Engl J Med. 2010: 440-447.
15. Davies I, O’Neill PA, McLean KA, et al. Age-associated alterations in thirst and arginine vasopressin in response to a water or sodium load. Age Ageing. 1995;24:151-159.
16. Rikkert MG, Melis RJ, Claassen JA. Heat waves and dehydration in the elderly. BMJ. 2009;339:b2663.-
17. Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Circulation. 1997;96:1224-1232.
18. Agostoni P, Cattadori G, Guazzi M, et al. Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med. 2000;109:450-455.
19. Higgins JP, Tuttle T, Higgins JA. Altitude and the heart: is going high safe for your cardiac patient? Am Heart J. 2010;159:25-32.
20. Gautret P, Schlagenhauf P, Gaudart J, et al. Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. Emerg Infect Dis. 2009;15:1783-1790.
21. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis. 2001;32:1706-1709.
22. Black RE. Epidemiology of travelers’ diarrhea and relative importance of various pathogens. Rev Infect Dis. 1990;12 (suppl 1):S73-S79.
23. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. Clin Infect Dis. 2002;34:628-633.
24. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect. 2004;10:868-876.
25. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341-345.
26. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37:1165-1171.
27. Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44:338-346.
28. Shanks GD, Smoak BL, Aleman GM, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group. Clin Infect Dis. 1999;29:942-943.
29. Heatley RV, Sobala GM. Acid suppression and the gastric flora. Baillieres Clin Gastroenterol. 1993;7:167-181.
30. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006;6:361-373.
31. Vaughn JA, Miller RA. Update on immunizations in adults. Am Fam Physician. 2011;84:1015-1020.
32. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332:761-766.
33. World Health Organization. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec. 2008;83:49-59.
34. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med. 2002;347:13-18.
35. Soto J, Medina F, Dember N, et al. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. Clin Infect Dis. 1995;21:599-602.
36. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359:603-612.
A stroke—or something else?
A 54-year-old white woman with a history of a cerebrovascular accident (CVA) a year earlier sought care at the local emergency department for numbness and weakness in her right foot. She reported no other neurologic symptoms. She had mild weakness in her right leg and a mildly unsteady gait. Her neurologic examination was otherwise normal.
Initial testing included a complete blood count (CBC), renal profile, and thyroid-stimulating hormone measurement. All results were normal. A noncontrast computed tomography (CT) scan of the head was normal. We admitted her for further evaluation of probable acute ischemic stroke.
By the following day, the patient’s leg weakness and unsteadiness had worsened. A magnetic resonance imaging (MRI) scan of her head showed a prior left pontine infarct, but no new findings. She developed right arm weakness, and an MRI scan of her spine (FIGURE 1) showed multiple intradural lesions. A lumbar puncture showed elevated protein and oligoclonal bands. CT scans of the chest, abdomen, and pelvis were unremarkable. Two lumbar punctures for cytology and culture evaluations yielded negative results. A full-body positron-emission tomography (PET) scan showed diffuse small inguinal adenopathy bilaterally, suggestive of metastatic disease or lymphoma.
FIGURE 1
MRI of the spine
This MRI scan with contrast of the patient’s spine shows diffuse thoracic extramedullary, intradural lesions.
What is your presumptive diagnosis?
Diagnosis: Sarcoidosis
Findings from the full-body PET scan (FIGURE 2) prompted a biopsy of a right inguinal node, which showed a noncaseating granuloma—a hallmark finding of sarcoidosis.
Sarcoidosis is a multisystem disease of unknown cause. The exact prevalence in the general population is estimated at 10 to 20 cases per 100,000.1 A higher incidence occurs in blacks in the United States, with a 2.4% lifetime risk compared with 0.85% of whites.2 Sarcoidosis usually appears in patients ages 20 to 40 years, and although this systemic disease usually affects the lungs, 5% to 10% of patients will have nervous system involvement.3,4
FIGURE 2
Full-body PET scan
This PET scan shows diffuse hypermetabolic adenopathy with bilateral iliac adenopathy, small hypermetabolic bilateral cervical lymph nodes, a hypermetabolic left axillary node, and a large hypermetabolic portacaval node.
What you’ll see
The most common presenting symptoms of systemic sarcoidosis are chronic cough, shortness of breath, and chest pain. Fatigue, weight loss, and myalgias are also frequently part of the initial presentation.
Patients with sarcoidosis can present with neurologic symptoms suggestive of many diseases (TABLE 1), and in the absence of systemic symptoms the diagnosis of neurosarcoidosis is easily confused with CVA. Most patients with neurosarcoidosis have cranial nerve involvement (50%-75%).1 Other common presentations include seizures, meningitis, psychiatric symptoms, mass lesions, or endocrine abnormalities.
TABLE 1
Differential diagnosis of an acute neurologic event
Infectious Encephalitis Helminthic infection HIV Lyme disease Meningitis Progressive multifocal leukoencephalopathy Syphilis Tuberculosis |
Neoplastic CNS lymphoma Meningioma/glioma Metastatic disease |
Neurologic CNS vasculitis Cranial nerve palsy Ischemic or hemorrhagic stroke Meningitis/encephalitis Multiple sclerosis Neurosarcoidosis Peripheral neuropathy Seizure |
Psychiatric Depression Malingering Pseudoseizures Somatoform disorder |
Rheumatologic Lupus erythematosus |
CNS, central nervous system; HIV, human immunodeficiency virus |
Useful studies in the clinical evaluation
Consider a diagnosis of sarcoidosis involving the nervous system when an initial work-up for CVA is negative. In addition to asking about systemic symptoms, perform a complete neurologic exam and skin exam, search for lymphadenopathy, and conduct an ophthalmologic evaluation. After the initial evaluation, a neurology consult will likely be needed to guide further testing.
Choice of serum studies will vary depending on presenting symptoms, but they usually include tests for infection (CBC, cultures, Lyme titers, rapid plasma reagin, tuberculin skin test), rheumatologic disorders (antinuclear antibodies, erythrocyte sedimentation rate, C-reactive protein), and neoplastic diseases (lactate dehydrogenase, peripheral smear).5 Serum angiotensin-converting enzyme (ACE) may be useful in the diagnosis of systemic sarcoidosis, with positive results seen in approximately 75% of cases.3
Examination of cerebrospinal fluid often reveals an elevated total protein with oligoclonal bands, normal to low glucose, and possibly mild pleocytosis of monocytic or lymphocytic predominance.3 Spinal fluid ACE is neither sensitive nor specific for neurosarcoidosis, as it may be elevated in infectious or malignant processes.3
Imaging studies should include contrast-enhanced brain MRI, which may reveal multiple white matter lesions.6 Although the specificity of PET for neurosarcoidosis is poor—with positive results being seen also in infectious and neoplastic processes—the scan may help in identifying extraneural sites for biopsy. Histology will generally show the classic noncaseating granuloma with surrounding lymphocytes, plasma cells, and mast cells.
Treat with high-dose steroids
The mainstay of treatment, based largely on expert opinion, is high-dose steroids that are gradually tapered over weeks (TABLE 2). Other agents may be added if the condition is poorly controlled with steroids alone, or may be given if symptoms recur while tapering the steroid dose. Recurrence of sarcoidosis is common after doses of <10 to 20 mg/d. Prophylactic measures to counteract the adverse effects of long-term steroid use include weight-bearing exercise programs; administration of calcium, vitamin D, and bisphosphonates; and resorting to a stress-dose steroid regimen in times of illness.
The prognosis with sarcoidosis can vary widely. Case studies show that two-thirds of patients may have a nonrecurring illness. Among the remaining one-third, the disease course may be relapsing-remitting or progressive. When confronted with an acute neurologic event, consider recurrent sarcoidosis and coordinate care between specialists. Also, take steps to prevent complications related to prolonged steroid use.
TABLE 2
Treatment of neurosarcoidosis3
Medication* | Side effects | Comments |
---|---|---|
Methylprednisolone | Hyperglycemia | |
Prednisone | Osteoporosis, hyperglycemia, hypertension, diabetes, glaucoma, cataracts, psychosis, Cushing’s syndrome | Taper as able. Concomitant use of cytotoxic agents may facilitate taper. Monitor glucose and give calcium/vitamin D prophylaxis |
Methotrexate | Anemia, neutropenia, liver damage | Weekly dosing well tolerated. Give folic acid 1 mg/d. Monitor liver function tests periodically |
Cyclosporine | Renal insufficiency, hypertension | |
Azathioprine | Anemia, neutropenia, liver damage | |
Cyclophosphamide | Cystitis, neutropenia | Monitor urine monthly for microscopic hematuria |
Hydroxychloroquine | Retinopathy, hypoglycemia, ototoxicity, myopathy, cardiomyopathy, neuropathy | Refer for eye exams every 3-6 months. May be useful to counteract hyperglycemic effect of steroids |
Infliximab | Fever, headache, dizziness, flushing, abdominal pain, dyspepsia, myalgia, arthralgia, polyneuropathy | Screen for tuberculosis before starting treatment. Contraindicated in patients with congestive heart failure |
*For dosing details, consult a neurologist or rheumatologist |
Improvement for our patient
Based on cerebrospinal fluid study results, a positive peripheral lymph node biopsy, and the exclusion of other diagnoses, we regarded the diagnosis of sarcoidosis as highly probable and initiated high-dose intravenous corticosteroids. Over several weeks, our patient gradually improved with physical therapy and was walking unassisted at the time of discharge from a hospital-based rehabilitation unit. Repeat MRI scans showed a reduction in the size of her intradural lesions, and we slowly tapered her steroids.
CORRESPONDENCE
Hillary R. Mount, MD, 2123 Auburn Avenue,#340, Cincinnati, OH 45219; hillary.mount@thechristhospital.com
1. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7:234-244.
2. Burns TM. Neurosarcoidosis. Arch Neurol. 2003;60:1166-1168.
3. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med. 2010;16:472-479.
4. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J. 2008;38:270-277.
5. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med. 2010;31:419-427.
6. Cavazza A, Harari S, Caminati A, et al. The histology of pulmonary sarcoidosis: a review with particular emphasis on unusual and underrecognized features. Int J Surg Pathol. 2009;17:219-230.
A 54-year-old white woman with a history of a cerebrovascular accident (CVA) a year earlier sought care at the local emergency department for numbness and weakness in her right foot. She reported no other neurologic symptoms. She had mild weakness in her right leg and a mildly unsteady gait. Her neurologic examination was otherwise normal.
Initial testing included a complete blood count (CBC), renal profile, and thyroid-stimulating hormone measurement. All results were normal. A noncontrast computed tomography (CT) scan of the head was normal. We admitted her for further evaluation of probable acute ischemic stroke.
By the following day, the patient’s leg weakness and unsteadiness had worsened. A magnetic resonance imaging (MRI) scan of her head showed a prior left pontine infarct, but no new findings. She developed right arm weakness, and an MRI scan of her spine (FIGURE 1) showed multiple intradural lesions. A lumbar puncture showed elevated protein and oligoclonal bands. CT scans of the chest, abdomen, and pelvis were unremarkable. Two lumbar punctures for cytology and culture evaluations yielded negative results. A full-body positron-emission tomography (PET) scan showed diffuse small inguinal adenopathy bilaterally, suggestive of metastatic disease or lymphoma.
FIGURE 1
MRI of the spine
This MRI scan with contrast of the patient’s spine shows diffuse thoracic extramedullary, intradural lesions.
What is your presumptive diagnosis?
Diagnosis: Sarcoidosis
Findings from the full-body PET scan (FIGURE 2) prompted a biopsy of a right inguinal node, which showed a noncaseating granuloma—a hallmark finding of sarcoidosis.
Sarcoidosis is a multisystem disease of unknown cause. The exact prevalence in the general population is estimated at 10 to 20 cases per 100,000.1 A higher incidence occurs in blacks in the United States, with a 2.4% lifetime risk compared with 0.85% of whites.2 Sarcoidosis usually appears in patients ages 20 to 40 years, and although this systemic disease usually affects the lungs, 5% to 10% of patients will have nervous system involvement.3,4
FIGURE 2
Full-body PET scan
This PET scan shows diffuse hypermetabolic adenopathy with bilateral iliac adenopathy, small hypermetabolic bilateral cervical lymph nodes, a hypermetabolic left axillary node, and a large hypermetabolic portacaval node.
What you’ll see
The most common presenting symptoms of systemic sarcoidosis are chronic cough, shortness of breath, and chest pain. Fatigue, weight loss, and myalgias are also frequently part of the initial presentation.
Patients with sarcoidosis can present with neurologic symptoms suggestive of many diseases (TABLE 1), and in the absence of systemic symptoms the diagnosis of neurosarcoidosis is easily confused with CVA. Most patients with neurosarcoidosis have cranial nerve involvement (50%-75%).1 Other common presentations include seizures, meningitis, psychiatric symptoms, mass lesions, or endocrine abnormalities.
TABLE 1
Differential diagnosis of an acute neurologic event
Infectious Encephalitis Helminthic infection HIV Lyme disease Meningitis Progressive multifocal leukoencephalopathy Syphilis Tuberculosis |
Neoplastic CNS lymphoma Meningioma/glioma Metastatic disease |
Neurologic CNS vasculitis Cranial nerve palsy Ischemic or hemorrhagic stroke Meningitis/encephalitis Multiple sclerosis Neurosarcoidosis Peripheral neuropathy Seizure |
Psychiatric Depression Malingering Pseudoseizures Somatoform disorder |
Rheumatologic Lupus erythematosus |
CNS, central nervous system; HIV, human immunodeficiency virus |
Useful studies in the clinical evaluation
Consider a diagnosis of sarcoidosis involving the nervous system when an initial work-up for CVA is negative. In addition to asking about systemic symptoms, perform a complete neurologic exam and skin exam, search for lymphadenopathy, and conduct an ophthalmologic evaluation. After the initial evaluation, a neurology consult will likely be needed to guide further testing.
Choice of serum studies will vary depending on presenting symptoms, but they usually include tests for infection (CBC, cultures, Lyme titers, rapid plasma reagin, tuberculin skin test), rheumatologic disorders (antinuclear antibodies, erythrocyte sedimentation rate, C-reactive protein), and neoplastic diseases (lactate dehydrogenase, peripheral smear).5 Serum angiotensin-converting enzyme (ACE) may be useful in the diagnosis of systemic sarcoidosis, with positive results seen in approximately 75% of cases.3
Examination of cerebrospinal fluid often reveals an elevated total protein with oligoclonal bands, normal to low glucose, and possibly mild pleocytosis of monocytic or lymphocytic predominance.3 Spinal fluid ACE is neither sensitive nor specific for neurosarcoidosis, as it may be elevated in infectious or malignant processes.3
Imaging studies should include contrast-enhanced brain MRI, which may reveal multiple white matter lesions.6 Although the specificity of PET for neurosarcoidosis is poor—with positive results being seen also in infectious and neoplastic processes—the scan may help in identifying extraneural sites for biopsy. Histology will generally show the classic noncaseating granuloma with surrounding lymphocytes, plasma cells, and mast cells.
Treat with high-dose steroids
The mainstay of treatment, based largely on expert opinion, is high-dose steroids that are gradually tapered over weeks (TABLE 2). Other agents may be added if the condition is poorly controlled with steroids alone, or may be given if symptoms recur while tapering the steroid dose. Recurrence of sarcoidosis is common after doses of <10 to 20 mg/d. Prophylactic measures to counteract the adverse effects of long-term steroid use include weight-bearing exercise programs; administration of calcium, vitamin D, and bisphosphonates; and resorting to a stress-dose steroid regimen in times of illness.
The prognosis with sarcoidosis can vary widely. Case studies show that two-thirds of patients may have a nonrecurring illness. Among the remaining one-third, the disease course may be relapsing-remitting or progressive. When confronted with an acute neurologic event, consider recurrent sarcoidosis and coordinate care between specialists. Also, take steps to prevent complications related to prolonged steroid use.
TABLE 2
Treatment of neurosarcoidosis3
Medication* | Side effects | Comments |
---|---|---|
Methylprednisolone | Hyperglycemia | |
Prednisone | Osteoporosis, hyperglycemia, hypertension, diabetes, glaucoma, cataracts, psychosis, Cushing’s syndrome | Taper as able. Concomitant use of cytotoxic agents may facilitate taper. Monitor glucose and give calcium/vitamin D prophylaxis |
Methotrexate | Anemia, neutropenia, liver damage | Weekly dosing well tolerated. Give folic acid 1 mg/d. Monitor liver function tests periodically |
Cyclosporine | Renal insufficiency, hypertension | |
Azathioprine | Anemia, neutropenia, liver damage | |
Cyclophosphamide | Cystitis, neutropenia | Monitor urine monthly for microscopic hematuria |
Hydroxychloroquine | Retinopathy, hypoglycemia, ototoxicity, myopathy, cardiomyopathy, neuropathy | Refer for eye exams every 3-6 months. May be useful to counteract hyperglycemic effect of steroids |
Infliximab | Fever, headache, dizziness, flushing, abdominal pain, dyspepsia, myalgia, arthralgia, polyneuropathy | Screen for tuberculosis before starting treatment. Contraindicated in patients with congestive heart failure |
*For dosing details, consult a neurologist or rheumatologist |
Improvement for our patient
Based on cerebrospinal fluid study results, a positive peripheral lymph node biopsy, and the exclusion of other diagnoses, we regarded the diagnosis of sarcoidosis as highly probable and initiated high-dose intravenous corticosteroids. Over several weeks, our patient gradually improved with physical therapy and was walking unassisted at the time of discharge from a hospital-based rehabilitation unit. Repeat MRI scans showed a reduction in the size of her intradural lesions, and we slowly tapered her steroids.
CORRESPONDENCE
Hillary R. Mount, MD, 2123 Auburn Avenue,#340, Cincinnati, OH 45219; hillary.mount@thechristhospital.com
A 54-year-old white woman with a history of a cerebrovascular accident (CVA) a year earlier sought care at the local emergency department for numbness and weakness in her right foot. She reported no other neurologic symptoms. She had mild weakness in her right leg and a mildly unsteady gait. Her neurologic examination was otherwise normal.
Initial testing included a complete blood count (CBC), renal profile, and thyroid-stimulating hormone measurement. All results were normal. A noncontrast computed tomography (CT) scan of the head was normal. We admitted her for further evaluation of probable acute ischemic stroke.
By the following day, the patient’s leg weakness and unsteadiness had worsened. A magnetic resonance imaging (MRI) scan of her head showed a prior left pontine infarct, but no new findings. She developed right arm weakness, and an MRI scan of her spine (FIGURE 1) showed multiple intradural lesions. A lumbar puncture showed elevated protein and oligoclonal bands. CT scans of the chest, abdomen, and pelvis were unremarkable. Two lumbar punctures for cytology and culture evaluations yielded negative results. A full-body positron-emission tomography (PET) scan showed diffuse small inguinal adenopathy bilaterally, suggestive of metastatic disease or lymphoma.
FIGURE 1
MRI of the spine
This MRI scan with contrast of the patient’s spine shows diffuse thoracic extramedullary, intradural lesions.
What is your presumptive diagnosis?
Diagnosis: Sarcoidosis
Findings from the full-body PET scan (FIGURE 2) prompted a biopsy of a right inguinal node, which showed a noncaseating granuloma—a hallmark finding of sarcoidosis.
Sarcoidosis is a multisystem disease of unknown cause. The exact prevalence in the general population is estimated at 10 to 20 cases per 100,000.1 A higher incidence occurs in blacks in the United States, with a 2.4% lifetime risk compared with 0.85% of whites.2 Sarcoidosis usually appears in patients ages 20 to 40 years, and although this systemic disease usually affects the lungs, 5% to 10% of patients will have nervous system involvement.3,4
FIGURE 2
Full-body PET scan
This PET scan shows diffuse hypermetabolic adenopathy with bilateral iliac adenopathy, small hypermetabolic bilateral cervical lymph nodes, a hypermetabolic left axillary node, and a large hypermetabolic portacaval node.
What you’ll see
The most common presenting symptoms of systemic sarcoidosis are chronic cough, shortness of breath, and chest pain. Fatigue, weight loss, and myalgias are also frequently part of the initial presentation.
Patients with sarcoidosis can present with neurologic symptoms suggestive of many diseases (TABLE 1), and in the absence of systemic symptoms the diagnosis of neurosarcoidosis is easily confused with CVA. Most patients with neurosarcoidosis have cranial nerve involvement (50%-75%).1 Other common presentations include seizures, meningitis, psychiatric symptoms, mass lesions, or endocrine abnormalities.
TABLE 1
Differential diagnosis of an acute neurologic event
Infectious Encephalitis Helminthic infection HIV Lyme disease Meningitis Progressive multifocal leukoencephalopathy Syphilis Tuberculosis |
Neoplastic CNS lymphoma Meningioma/glioma Metastatic disease |
Neurologic CNS vasculitis Cranial nerve palsy Ischemic or hemorrhagic stroke Meningitis/encephalitis Multiple sclerosis Neurosarcoidosis Peripheral neuropathy Seizure |
Psychiatric Depression Malingering Pseudoseizures Somatoform disorder |
Rheumatologic Lupus erythematosus |
CNS, central nervous system; HIV, human immunodeficiency virus |
Useful studies in the clinical evaluation
Consider a diagnosis of sarcoidosis involving the nervous system when an initial work-up for CVA is negative. In addition to asking about systemic symptoms, perform a complete neurologic exam and skin exam, search for lymphadenopathy, and conduct an ophthalmologic evaluation. After the initial evaluation, a neurology consult will likely be needed to guide further testing.
Choice of serum studies will vary depending on presenting symptoms, but they usually include tests for infection (CBC, cultures, Lyme titers, rapid plasma reagin, tuberculin skin test), rheumatologic disorders (antinuclear antibodies, erythrocyte sedimentation rate, C-reactive protein), and neoplastic diseases (lactate dehydrogenase, peripheral smear).5 Serum angiotensin-converting enzyme (ACE) may be useful in the diagnosis of systemic sarcoidosis, with positive results seen in approximately 75% of cases.3
Examination of cerebrospinal fluid often reveals an elevated total protein with oligoclonal bands, normal to low glucose, and possibly mild pleocytosis of monocytic or lymphocytic predominance.3 Spinal fluid ACE is neither sensitive nor specific for neurosarcoidosis, as it may be elevated in infectious or malignant processes.3
Imaging studies should include contrast-enhanced brain MRI, which may reveal multiple white matter lesions.6 Although the specificity of PET for neurosarcoidosis is poor—with positive results being seen also in infectious and neoplastic processes—the scan may help in identifying extraneural sites for biopsy. Histology will generally show the classic noncaseating granuloma with surrounding lymphocytes, plasma cells, and mast cells.
Treat with high-dose steroids
The mainstay of treatment, based largely on expert opinion, is high-dose steroids that are gradually tapered over weeks (TABLE 2). Other agents may be added if the condition is poorly controlled with steroids alone, or may be given if symptoms recur while tapering the steroid dose. Recurrence of sarcoidosis is common after doses of <10 to 20 mg/d. Prophylactic measures to counteract the adverse effects of long-term steroid use include weight-bearing exercise programs; administration of calcium, vitamin D, and bisphosphonates; and resorting to a stress-dose steroid regimen in times of illness.
The prognosis with sarcoidosis can vary widely. Case studies show that two-thirds of patients may have a nonrecurring illness. Among the remaining one-third, the disease course may be relapsing-remitting or progressive. When confronted with an acute neurologic event, consider recurrent sarcoidosis and coordinate care between specialists. Also, take steps to prevent complications related to prolonged steroid use.
TABLE 2
Treatment of neurosarcoidosis3
Medication* | Side effects | Comments |
---|---|---|
Methylprednisolone | Hyperglycemia | |
Prednisone | Osteoporosis, hyperglycemia, hypertension, diabetes, glaucoma, cataracts, psychosis, Cushing’s syndrome | Taper as able. Concomitant use of cytotoxic agents may facilitate taper. Monitor glucose and give calcium/vitamin D prophylaxis |
Methotrexate | Anemia, neutropenia, liver damage | Weekly dosing well tolerated. Give folic acid 1 mg/d. Monitor liver function tests periodically |
Cyclosporine | Renal insufficiency, hypertension | |
Azathioprine | Anemia, neutropenia, liver damage | |
Cyclophosphamide | Cystitis, neutropenia | Monitor urine monthly for microscopic hematuria |
Hydroxychloroquine | Retinopathy, hypoglycemia, ototoxicity, myopathy, cardiomyopathy, neuropathy | Refer for eye exams every 3-6 months. May be useful to counteract hyperglycemic effect of steroids |
Infliximab | Fever, headache, dizziness, flushing, abdominal pain, dyspepsia, myalgia, arthralgia, polyneuropathy | Screen for tuberculosis before starting treatment. Contraindicated in patients with congestive heart failure |
*For dosing details, consult a neurologist or rheumatologist |
Improvement for our patient
Based on cerebrospinal fluid study results, a positive peripheral lymph node biopsy, and the exclusion of other diagnoses, we regarded the diagnosis of sarcoidosis as highly probable and initiated high-dose intravenous corticosteroids. Over several weeks, our patient gradually improved with physical therapy and was walking unassisted at the time of discharge from a hospital-based rehabilitation unit. Repeat MRI scans showed a reduction in the size of her intradural lesions, and we slowly tapered her steroids.
CORRESPONDENCE
Hillary R. Mount, MD, 2123 Auburn Avenue,#340, Cincinnati, OH 45219; hillary.mount@thechristhospital.com
1. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7:234-244.
2. Burns TM. Neurosarcoidosis. Arch Neurol. 2003;60:1166-1168.
3. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med. 2010;16:472-479.
4. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J. 2008;38:270-277.
5. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med. 2010;31:419-427.
6. Cavazza A, Harari S, Caminati A, et al. The histology of pulmonary sarcoidosis: a review with particular emphasis on unusual and underrecognized features. Int J Surg Pathol. 2009;17:219-230.
1. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7:234-244.
2. Burns TM. Neurosarcoidosis. Arch Neurol. 2003;60:1166-1168.
3. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med. 2010;16:472-479.
4. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J. 2008;38:270-277.
5. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med. 2010;31:419-427.
6. Cavazza A, Harari S, Caminati A, et al. The histology of pulmonary sarcoidosis: a review with particular emphasis on unusual and underrecognized features. Int J Surg Pathol. 2009;17:219-230.
A refractory case of community-acquired pneumonia
CASE: A 26-year-old woman came to our emergency department with shortness of breath—a symptom that had begun 2 weeks earlier and was getting steadily worse. She had a history of severe, persistent asthma, and had been admitted to the ICU—but not intubated—9 months earlier. Now, she reported dyspnea with even mild exertion, which inhalers failed to relieve.
The patient also had a cough and had recently begun producing thick, green sputum, but said she’d had no chest pain, fever, or lower extremity swelling. The young woman lived with her parents, both of whom smoked heavily, but denied tobacco or alcohol use herself. She had not taken antibiotics in the past 6 months.
On physical examination, the patient was afebrile, mildly tachypneic, and had a heart rate of 125 bpm. She was saturating 80% on ambient air and 95% on 2 liters per minute via nasal cannula; her lung exam was significant for diffuse wheezes and rhonchi, but the remainder of the physical exam was normal.
Lab tests revealed a white blood cell count of 25,200/mcL, with 81% neutrophils. Blood and urine cultures were preliminarily negative. We sent a sputum sample to be cultured and took chest x-rays. Posterior-anterior (PA) (FIGURE 1) and lateral (FIGURE 2) radiographs showed a dense right lower lobe inflltrate.
We diagnosed community-acquired pneumonia (CAP), coupled with an acute exacerbation of asthma, and admitted the patient to the hospital. We started her on intravenous (IV) moxifloxacin, parenteral steroids, and nebulized albuterol and ipratropium. But by the patient’s third day in the hospital, her white blood cell count had climbed to 34,500/mcL, and she still required oxygen by nasal cannula.
FIGURE 1 PA x-ray shows right lower lobe infiltrate
FIGURE 2 Dense infiltrate on lateral view
WHY DIDN’T THIS PATIENT RESPOND TO DRUG THERAPY?
CAP complicated by CA-MRSA
Initially, this appeared to be a rather straightforward case of CAP and asthma. The return of the sputum cultures on day 4, showing positive results for methicillin-resistant Staphylococcus aureus (MRSA), indicated that this was not the case. Sensitivity analysis revealed intermediate susceptibility to moxifloxacin and sensitivity to trimethoprim-sulfamethoxazole (TMP-SMX), vancomycin, and linezolid.
We switched the patient’s antibiotic from moxifloxacin to parenteral linezolid. She responded rapidly. On day 5, the patient was successfully weaned from O2 and converted to oral linezolid; the following day, she was discharged, with orders to complete an 8-day course of linezolid and an appointment with her family physician for the following week. At follow-up, she was doing well.
Cultures are crucial if results would alter Tx
In 2007, the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) published guidelines on the management of CAP1—a clinical diagnosis based on the presence of select features, including cough, fever, sputum production, and pleuritic chest pain. (Imaging of the chest may be used to support the diagnosis, but is not required.)
Following a site-of-care decision, ideally made with the help of a severity-of-illness scoring system such as the CURB-65 (Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and older) or Pneumonia Severity Index, the guidelines recommend cultures whenever the result is likely to significantly alter standard empiric treatment.1
Pretreatment blood samples for culture should be obtained (strength of recommendation: A, well-conducted randomized controlled trials). The IDSA/ATS CAP guidelines also recommend an expectorated sputum sample for stain and culture for patients admitted to the ICU, as well as for those with a presentation suggestive of CAP who:
- have failed outpatient treatment;
- abuse alcohol;
- have severe structural or obstructive lung disease;
- or have pleural effusion.1
In our patient’s case, we obtained a sputum culture on admission because of her severe asthma. She was persistently hypoxic during her initial days in the hospital, and when the sputum culture returned positive for MRSA, her regimen of antibiotics was adjusted.
Suspect CA-MRSA when CAP is severe
Although MRSA has traditionally been thought of as a nosocomial pathogen, infections caused by distinct CA-MRSA strains are on the rise. An estimated 1% to 10% of CAP cases are caused by S aureus, but the percentage of those strains that are resistant to methicillin is not known.2
Clinical risk factors for S aureus CAP include end-stage renal disease, injection drug use, prior influenza, and prior antibiotic therapy, especially with fluoroquinolones.1 How-ever, CA-MRSA CAP often affects children and healthy young adults without any risk factors.3,4
Additionally, CAP that is caused by CA-MRSA is typically severe, often involving empyema, acute respiratory distress syndrome (ARDS), cavitary pneumonia, or severe sepsis.5 Consider a diagnosis of CA-MRSA CAP in patients who present with cavitary infiltrates without risk factors for anaerobic aspiration, such as syncope, seizures, alcohol abuse, or esophageal motility disorders.1
Start treatment without delay in patients at risk
Standard empiric treatment options for hospitalized patients with CAP (with the exception of those in the ICU) include either a beta-lactam and azithromycin or a respiratory fluoroquinolone (neither of which is active against MRSA).1 All patients who are hospitalized for CAP should be started on this regimen without delay. If gram-positive cocci in clusters suggestive of S aureus are isolated from sputum, this standard empiric regimen should be adequate until further microbiologic identification is available.1 While most cases of S aureus CAP are not MRSA, the increased mortality rate associated with inappropriate antibiotic selection led the IDSA/ATS to recommend broader empiric coverage for MRSA for patients with risk factors for S aureus.1
CA-MRSA strains are distinct from their nosocomial counterpart, and the optimal therapy for confirmed CA-MRSA CAP has not been determined. Frequently, CA-MRSA isolates are sensitive to TMP-SMX, clindamycin, and fluoroquinolones. But neither fluoroquinolones nor TMP-SMX have a clear effect on toxin production, and bacterial resistance frequently emerges during therapy with clindamycin.1
The IDSA/ATS guidelines recommend either vancomycin or linezolid for CAP due to CA-MRSA, and these are the most widely used drugs for invasive CA-MRSA infections. Linezolid has been recognized as having a theoretical advantage in treating pneumonia, as it achieves higher lung epithelial concentrations than vancomycin.6 Particularly in cases of necrotizing CA-MRSA pneumonia, vancomycin has not been found to decrease toxin production, and linezolid is therefore the preferred treatment.1 Because of the limitations of vancomycin, we chose linezolid for our patient.
Treatment duration is not evidence-based
Although most patients with CAP are treated for 7 to 10 days, there are few well-designed studies evaluating the optimal time frame. Guidelines for the duration of antibiotics for CAP recommend a minimum of 5 days of therapy, presuming the patient is clinically stable.1,7 Short-duration therapy for patients with bacteremic S aureus CAP infection has been associated with an increased risk of endocarditis, and the presence of pulmonary cavities may warrant prolonged therapy.1 Our patient had an isolate of S aureus with intermediate susceptibility to moxifloxacin, which likely explains her rapid response to linezolid. She remained on linezolid for 8 days.
• Consider CA-MRSA as a cause of CAP, especially in cases in which the presentation is severe, as the guidelines for empiric treatment of CAP feature antibiotics that are not active against the CA-MRSA pathogen.
• Order sputum cultures for all patients admitted to the ICU, as well as for patients with a clinical presentation suggestive of CAP who abuse alcohol, have severe asthma or other lung disease, or have a pleural effusion.
• Start patients with CA-MRSA CAP on linezolid without delay.
The author reported no potential conflict of interest relevant to this article.
1. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS Guidelines for CAP in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Hidron AI, Low CE, Honig EG, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotizing community-onset pneumonia. Lancet Infect Dis. 2009;9:384-392.
3. Torell E, Molin D, Tano E, et al. CAP and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scandinavian J Inf Dis. 2005;37:902-904.
4. Soderquist B, Berglund C, Stralin K. CAP and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. Eur J Clin Microbiol Infec Dis. 2006;25:604-606.
5. Mizell KN, Patterson KV, Carter JE. Empyema necessitatis due to methicillin-resistant Staphylococcus aureus: case report and review of the literature. J Clin Microbiol. 2008;46:3534-3536.
6. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for CAP: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760.
7. Martino JL, McMillian WD, Polish LB, et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Resp Med. 2008;102:932-943.
CORRESPONDENCE Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati, Family Medicine Residency, 2123 Auburn Avenue, Suite 340, Cincinnati, OH 45219; schlaj@fammed.uc.edu
CASE: A 26-year-old woman came to our emergency department with shortness of breath—a symptom that had begun 2 weeks earlier and was getting steadily worse. She had a history of severe, persistent asthma, and had been admitted to the ICU—but not intubated—9 months earlier. Now, she reported dyspnea with even mild exertion, which inhalers failed to relieve.
The patient also had a cough and had recently begun producing thick, green sputum, but said she’d had no chest pain, fever, or lower extremity swelling. The young woman lived with her parents, both of whom smoked heavily, but denied tobacco or alcohol use herself. She had not taken antibiotics in the past 6 months.
On physical examination, the patient was afebrile, mildly tachypneic, and had a heart rate of 125 bpm. She was saturating 80% on ambient air and 95% on 2 liters per minute via nasal cannula; her lung exam was significant for diffuse wheezes and rhonchi, but the remainder of the physical exam was normal.
Lab tests revealed a white blood cell count of 25,200/mcL, with 81% neutrophils. Blood and urine cultures were preliminarily negative. We sent a sputum sample to be cultured and took chest x-rays. Posterior-anterior (PA) (FIGURE 1) and lateral (FIGURE 2) radiographs showed a dense right lower lobe inflltrate.
We diagnosed community-acquired pneumonia (CAP), coupled with an acute exacerbation of asthma, and admitted the patient to the hospital. We started her on intravenous (IV) moxifloxacin, parenteral steroids, and nebulized albuterol and ipratropium. But by the patient’s third day in the hospital, her white blood cell count had climbed to 34,500/mcL, and she still required oxygen by nasal cannula.
FIGURE 1 PA x-ray shows right lower lobe infiltrate
FIGURE 2 Dense infiltrate on lateral view
WHY DIDN’T THIS PATIENT RESPOND TO DRUG THERAPY?
CAP complicated by CA-MRSA
Initially, this appeared to be a rather straightforward case of CAP and asthma. The return of the sputum cultures on day 4, showing positive results for methicillin-resistant Staphylococcus aureus (MRSA), indicated that this was not the case. Sensitivity analysis revealed intermediate susceptibility to moxifloxacin and sensitivity to trimethoprim-sulfamethoxazole (TMP-SMX), vancomycin, and linezolid.
We switched the patient’s antibiotic from moxifloxacin to parenteral linezolid. She responded rapidly. On day 5, the patient was successfully weaned from O2 and converted to oral linezolid; the following day, she was discharged, with orders to complete an 8-day course of linezolid and an appointment with her family physician for the following week. At follow-up, she was doing well.
Cultures are crucial if results would alter Tx
In 2007, the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) published guidelines on the management of CAP1—a clinical diagnosis based on the presence of select features, including cough, fever, sputum production, and pleuritic chest pain. (Imaging of the chest may be used to support the diagnosis, but is not required.)
Following a site-of-care decision, ideally made with the help of a severity-of-illness scoring system such as the CURB-65 (Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and older) or Pneumonia Severity Index, the guidelines recommend cultures whenever the result is likely to significantly alter standard empiric treatment.1
Pretreatment blood samples for culture should be obtained (strength of recommendation: A, well-conducted randomized controlled trials). The IDSA/ATS CAP guidelines also recommend an expectorated sputum sample for stain and culture for patients admitted to the ICU, as well as for those with a presentation suggestive of CAP who:
- have failed outpatient treatment;
- abuse alcohol;
- have severe structural or obstructive lung disease;
- or have pleural effusion.1
In our patient’s case, we obtained a sputum culture on admission because of her severe asthma. She was persistently hypoxic during her initial days in the hospital, and when the sputum culture returned positive for MRSA, her regimen of antibiotics was adjusted.
Suspect CA-MRSA when CAP is severe
Although MRSA has traditionally been thought of as a nosocomial pathogen, infections caused by distinct CA-MRSA strains are on the rise. An estimated 1% to 10% of CAP cases are caused by S aureus, but the percentage of those strains that are resistant to methicillin is not known.2
Clinical risk factors for S aureus CAP include end-stage renal disease, injection drug use, prior influenza, and prior antibiotic therapy, especially with fluoroquinolones.1 How-ever, CA-MRSA CAP often affects children and healthy young adults without any risk factors.3,4
Additionally, CAP that is caused by CA-MRSA is typically severe, often involving empyema, acute respiratory distress syndrome (ARDS), cavitary pneumonia, or severe sepsis.5 Consider a diagnosis of CA-MRSA CAP in patients who present with cavitary infiltrates without risk factors for anaerobic aspiration, such as syncope, seizures, alcohol abuse, or esophageal motility disorders.1
Start treatment without delay in patients at risk
Standard empiric treatment options for hospitalized patients with CAP (with the exception of those in the ICU) include either a beta-lactam and azithromycin or a respiratory fluoroquinolone (neither of which is active against MRSA).1 All patients who are hospitalized for CAP should be started on this regimen without delay. If gram-positive cocci in clusters suggestive of S aureus are isolated from sputum, this standard empiric regimen should be adequate until further microbiologic identification is available.1 While most cases of S aureus CAP are not MRSA, the increased mortality rate associated with inappropriate antibiotic selection led the IDSA/ATS to recommend broader empiric coverage for MRSA for patients with risk factors for S aureus.1
CA-MRSA strains are distinct from their nosocomial counterpart, and the optimal therapy for confirmed CA-MRSA CAP has not been determined. Frequently, CA-MRSA isolates are sensitive to TMP-SMX, clindamycin, and fluoroquinolones. But neither fluoroquinolones nor TMP-SMX have a clear effect on toxin production, and bacterial resistance frequently emerges during therapy with clindamycin.1
The IDSA/ATS guidelines recommend either vancomycin or linezolid for CAP due to CA-MRSA, and these are the most widely used drugs for invasive CA-MRSA infections. Linezolid has been recognized as having a theoretical advantage in treating pneumonia, as it achieves higher lung epithelial concentrations than vancomycin.6 Particularly in cases of necrotizing CA-MRSA pneumonia, vancomycin has not been found to decrease toxin production, and linezolid is therefore the preferred treatment.1 Because of the limitations of vancomycin, we chose linezolid for our patient.
Treatment duration is not evidence-based
Although most patients with CAP are treated for 7 to 10 days, there are few well-designed studies evaluating the optimal time frame. Guidelines for the duration of antibiotics for CAP recommend a minimum of 5 days of therapy, presuming the patient is clinically stable.1,7 Short-duration therapy for patients with bacteremic S aureus CAP infection has been associated with an increased risk of endocarditis, and the presence of pulmonary cavities may warrant prolonged therapy.1 Our patient had an isolate of S aureus with intermediate susceptibility to moxifloxacin, which likely explains her rapid response to linezolid. She remained on linezolid for 8 days.
• Consider CA-MRSA as a cause of CAP, especially in cases in which the presentation is severe, as the guidelines for empiric treatment of CAP feature antibiotics that are not active against the CA-MRSA pathogen.
• Order sputum cultures for all patients admitted to the ICU, as well as for patients with a clinical presentation suggestive of CAP who abuse alcohol, have severe asthma or other lung disease, or have a pleural effusion.
• Start patients with CA-MRSA CAP on linezolid without delay.
The author reported no potential conflict of interest relevant to this article.
CASE: A 26-year-old woman came to our emergency department with shortness of breath—a symptom that had begun 2 weeks earlier and was getting steadily worse. She had a history of severe, persistent asthma, and had been admitted to the ICU—but not intubated—9 months earlier. Now, she reported dyspnea with even mild exertion, which inhalers failed to relieve.
The patient also had a cough and had recently begun producing thick, green sputum, but said she’d had no chest pain, fever, or lower extremity swelling. The young woman lived with her parents, both of whom smoked heavily, but denied tobacco or alcohol use herself. She had not taken antibiotics in the past 6 months.
On physical examination, the patient was afebrile, mildly tachypneic, and had a heart rate of 125 bpm. She was saturating 80% on ambient air and 95% on 2 liters per minute via nasal cannula; her lung exam was significant for diffuse wheezes and rhonchi, but the remainder of the physical exam was normal.
Lab tests revealed a white blood cell count of 25,200/mcL, with 81% neutrophils. Blood and urine cultures were preliminarily negative. We sent a sputum sample to be cultured and took chest x-rays. Posterior-anterior (PA) (FIGURE 1) and lateral (FIGURE 2) radiographs showed a dense right lower lobe inflltrate.
We diagnosed community-acquired pneumonia (CAP), coupled with an acute exacerbation of asthma, and admitted the patient to the hospital. We started her on intravenous (IV) moxifloxacin, parenteral steroids, and nebulized albuterol and ipratropium. But by the patient’s third day in the hospital, her white blood cell count had climbed to 34,500/mcL, and she still required oxygen by nasal cannula.
FIGURE 1 PA x-ray shows right lower lobe infiltrate
FIGURE 2 Dense infiltrate on lateral view
WHY DIDN’T THIS PATIENT RESPOND TO DRUG THERAPY?
CAP complicated by CA-MRSA
Initially, this appeared to be a rather straightforward case of CAP and asthma. The return of the sputum cultures on day 4, showing positive results for methicillin-resistant Staphylococcus aureus (MRSA), indicated that this was not the case. Sensitivity analysis revealed intermediate susceptibility to moxifloxacin and sensitivity to trimethoprim-sulfamethoxazole (TMP-SMX), vancomycin, and linezolid.
We switched the patient’s antibiotic from moxifloxacin to parenteral linezolid. She responded rapidly. On day 5, the patient was successfully weaned from O2 and converted to oral linezolid; the following day, she was discharged, with orders to complete an 8-day course of linezolid and an appointment with her family physician for the following week. At follow-up, she was doing well.
Cultures are crucial if results would alter Tx
In 2007, the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) published guidelines on the management of CAP1—a clinical diagnosis based on the presence of select features, including cough, fever, sputum production, and pleuritic chest pain. (Imaging of the chest may be used to support the diagnosis, but is not required.)
Following a site-of-care decision, ideally made with the help of a severity-of-illness scoring system such as the CURB-65 (Confusion, Urea nitrogen, Respiratory rate, Blood pressure, 65 years of age and older) or Pneumonia Severity Index, the guidelines recommend cultures whenever the result is likely to significantly alter standard empiric treatment.1
Pretreatment blood samples for culture should be obtained (strength of recommendation: A, well-conducted randomized controlled trials). The IDSA/ATS CAP guidelines also recommend an expectorated sputum sample for stain and culture for patients admitted to the ICU, as well as for those with a presentation suggestive of CAP who:
- have failed outpatient treatment;
- abuse alcohol;
- have severe structural or obstructive lung disease;
- or have pleural effusion.1
In our patient’s case, we obtained a sputum culture on admission because of her severe asthma. She was persistently hypoxic during her initial days in the hospital, and when the sputum culture returned positive for MRSA, her regimen of antibiotics was adjusted.
Suspect CA-MRSA when CAP is severe
Although MRSA has traditionally been thought of as a nosocomial pathogen, infections caused by distinct CA-MRSA strains are on the rise. An estimated 1% to 10% of CAP cases are caused by S aureus, but the percentage of those strains that are resistant to methicillin is not known.2
Clinical risk factors for S aureus CAP include end-stage renal disease, injection drug use, prior influenza, and prior antibiotic therapy, especially with fluoroquinolones.1 How-ever, CA-MRSA CAP often affects children and healthy young adults without any risk factors.3,4
Additionally, CAP that is caused by CA-MRSA is typically severe, often involving empyema, acute respiratory distress syndrome (ARDS), cavitary pneumonia, or severe sepsis.5 Consider a diagnosis of CA-MRSA CAP in patients who present with cavitary infiltrates without risk factors for anaerobic aspiration, such as syncope, seizures, alcohol abuse, or esophageal motility disorders.1
Start treatment without delay in patients at risk
Standard empiric treatment options for hospitalized patients with CAP (with the exception of those in the ICU) include either a beta-lactam and azithromycin or a respiratory fluoroquinolone (neither of which is active against MRSA).1 All patients who are hospitalized for CAP should be started on this regimen without delay. If gram-positive cocci in clusters suggestive of S aureus are isolated from sputum, this standard empiric regimen should be adequate until further microbiologic identification is available.1 While most cases of S aureus CAP are not MRSA, the increased mortality rate associated with inappropriate antibiotic selection led the IDSA/ATS to recommend broader empiric coverage for MRSA for patients with risk factors for S aureus.1
CA-MRSA strains are distinct from their nosocomial counterpart, and the optimal therapy for confirmed CA-MRSA CAP has not been determined. Frequently, CA-MRSA isolates are sensitive to TMP-SMX, clindamycin, and fluoroquinolones. But neither fluoroquinolones nor TMP-SMX have a clear effect on toxin production, and bacterial resistance frequently emerges during therapy with clindamycin.1
The IDSA/ATS guidelines recommend either vancomycin or linezolid for CAP due to CA-MRSA, and these are the most widely used drugs for invasive CA-MRSA infections. Linezolid has been recognized as having a theoretical advantage in treating pneumonia, as it achieves higher lung epithelial concentrations than vancomycin.6 Particularly in cases of necrotizing CA-MRSA pneumonia, vancomycin has not been found to decrease toxin production, and linezolid is therefore the preferred treatment.1 Because of the limitations of vancomycin, we chose linezolid for our patient.
Treatment duration is not evidence-based
Although most patients with CAP are treated for 7 to 10 days, there are few well-designed studies evaluating the optimal time frame. Guidelines for the duration of antibiotics for CAP recommend a minimum of 5 days of therapy, presuming the patient is clinically stable.1,7 Short-duration therapy for patients with bacteremic S aureus CAP infection has been associated with an increased risk of endocarditis, and the presence of pulmonary cavities may warrant prolonged therapy.1 Our patient had an isolate of S aureus with intermediate susceptibility to moxifloxacin, which likely explains her rapid response to linezolid. She remained on linezolid for 8 days.
• Consider CA-MRSA as a cause of CAP, especially in cases in which the presentation is severe, as the guidelines for empiric treatment of CAP feature antibiotics that are not active against the CA-MRSA pathogen.
• Order sputum cultures for all patients admitted to the ICU, as well as for patients with a clinical presentation suggestive of CAP who abuse alcohol, have severe asthma or other lung disease, or have a pleural effusion.
• Start patients with CA-MRSA CAP on linezolid without delay.
The author reported no potential conflict of interest relevant to this article.
1. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS Guidelines for CAP in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Hidron AI, Low CE, Honig EG, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotizing community-onset pneumonia. Lancet Infect Dis. 2009;9:384-392.
3. Torell E, Molin D, Tano E, et al. CAP and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scandinavian J Inf Dis. 2005;37:902-904.
4. Soderquist B, Berglund C, Stralin K. CAP and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. Eur J Clin Microbiol Infec Dis. 2006;25:604-606.
5. Mizell KN, Patterson KV, Carter JE. Empyema necessitatis due to methicillin-resistant Staphylococcus aureus: case report and review of the literature. J Clin Microbiol. 2008;46:3534-3536.
6. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for CAP: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760.
7. Martino JL, McMillian WD, Polish LB, et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Resp Med. 2008;102:932-943.
CORRESPONDENCE Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati, Family Medicine Residency, 2123 Auburn Avenue, Suite 340, Cincinnati, OH 45219; schlaj@fammed.uc.edu
1. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS Guidelines for CAP in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
2. Hidron AI, Low CE, Honig EG, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotizing community-onset pneumonia. Lancet Infect Dis. 2009;9:384-392.
3. Torell E, Molin D, Tano E, et al. CAP and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scandinavian J Inf Dis. 2005;37:902-904.
4. Soderquist B, Berglund C, Stralin K. CAP and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. Eur J Clin Microbiol Infec Dis. 2006;25:604-606.
5. Mizell KN, Patterson KV, Carter JE. Empyema necessitatis due to methicillin-resistant Staphylococcus aureus: case report and review of the literature. J Clin Microbiol. 2008;46:3534-3536.
6. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for CAP: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760.
7. Martino JL, McMillian WD, Polish LB, et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Resp Med. 2008;102:932-943.
CORRESPONDENCE Jeffrey D. Schlaudecker, MD, The Christ Hospital/University of Cincinnati, Family Medicine Residency, 2123 Auburn Avenue, Suite 340, Cincinnati, OH 45219; schlaj@fammed.uc.edu